OMNICOMM SYSTEMS INC - FORM 10-Q

Attached files

file	filename
EX-10.58 - EXHIBIT 10.58 - OMNICOMM SYSTEMS INC	ex_100280.htm
EX-10.48 - EXHIBIT 10.48 - OMNICOMM SYSTEMS INC	ex_100277.htm
EX-10.47 - EXHIBIT 10.47 - OMNICOMM SYSTEMS INC	ex_100276.htm
EX-32.1 - EXHIBIT 32.1 - OMNICOMM SYSTEMS INC	ex_99248.htm
EX-31.2 - EXHIBIT 31.2 - OMNICOMM SYSTEMS INC	ex_99240.htm
EX-31.1 - EXHIBIT 31.1 - OMNICOMM SYSTEMS INC	ex_99239.htm

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 10-Q

[Mark One]

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2017

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from _______ to ________

Commission File Number: 0-25203

OmniComm Systems, Inc.
(Exact name of registrant as specified in its Charter)

Delaware	11-3349762
(State or other jurisdiction of Incorporation or organization)	(IRS Employer Identification Number)

2101 W. Commercial Blvd. Suite 3500, Fort Lauderdale, FL	33309
Address of principal executive offices	Zip Code

954.473.1254
(Registrant’s Telephone Number including area code)

No Changes

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [√] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [√] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

[ ]

Accelerated filer

[ ]

Non-accelerated filer

(Do not check if smaller reporting company)

[ ]

Smaller reporting company

[√]

Emerging growth company

[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [√]

The number of shares outstanding of each of the issuer’s classes of common equity as of November 10, 2017: 148,042,805 common stock $.001 par value.

Table of Contents

Table of Contents to the Quarterly Report on Form 10-Q for the Nine month period ended September 30, 2017

PART I. FINANCIAL INFORMATION	3
ITEM 1. FINANCIAL STATEMENTS	3
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	36
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	52
ITEM 4. CONTROLS AND PROCEDURES	52
PART II. OTHER INFORMATION	52
ITEM 1. LEGAL PROCEEDINGS	52
ITEM 1A. RISK FACTORS	52
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	52
ITEM 3. DEFAULTS UPON SENIOR SECURITIES	52
ITEM 4. MINE SAFETY DISCLOSURES	53
ITEM 5. OTHER INFORMATION	53
ITEM 6. EXHIBITS	53
SIGNATURES	54

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

	September 30, 2017			December 31, 2016
	(unaudited)
ASSETS

CURRENT ASSETS
Cash	$	1,317,591		$	1,439,332
Accounts receivable, net of allowance for doubtful accounts of $220,182 and $179,813, respectively		5,415,730			5,455,210
Prepaid expenses		243,434			195,915
Prepaid stock compensation, current portion		-0-			148,422
Other current assets		32,140			35,055
Total current assets		7,008,895			7,273,934
Property and equipment, net		608,226			637,552
Other assets
Intangible assets, net		102,248			108,880
Prepaid stock compensation		-0-			58,663
Other assets		46,478			51,321

TOTAL ASSETS	$	7,765,847		$	8,130,350

LIABILITIES AND SHAREHOLDERS' (DEFICIT)

CURRENT LIABILITIES
Accounts payable and accrued expenses	$	1,612,757		$	2,123,073
Deferred revenue, current portion		7,131,466			7,250,061
Convertible notes payable, current portion		50,000			50,000
Patent settlement liability, current portion		521,723			862,500
Conversion feature liability, related parties		1,555,297			1,740,278
Conversion feature liability		86,913			585,452
Warrant liability, related parties		2,317,324			2,519,614
Warrant liability		1,239,459			1,479,748
Total current liabilities		14,514,939			16,610,726

LONG TERM LIABILITIES
Line of credit, long term		2,500,000			2,700,000
Notes payable, related parties, long term, net of current portion, net of discount of $140,838 and $237,664, respectively		259,162			212,336
Notes payable, long term, net of current portion, net of discount of $310,447 and $455,285, respectively		392,053			337,215
Deferred revenue, long term, net of current portion		2,000,897			2,289,169
Convertible notes payable, related parties, long term, net of current portion		5,770,000			5,825,000
Convertible notes payable, long term, net of current portion		350,000			1,175,000
Patent settlement liability, long term, net of current portion		-0-			108,702

TOTAL LIABILITIES		25,787,051			29,258,148

COMMITMENTS AND CONTINGENCIES (See Note 10)

SHAREHOLDERS' (DEFICIT)
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 3,772,500 shares undesignated
Series A convertible preferred stock, 5,000,000 shares authorized, -0- and -0- issued and outstanding, respectively at $0.001 par value; liquidation preference $-0- and $-0-, respectively		-0-			-0-
Series B convertible preferred stock, 230,000 shares authorized, -0- and -0- issued and outstanding, respectively at $0.001 par value; liquidation preference $-0- and $-0-, respectively		-0-			-0-
Series C convertible preferred stock, 747,500 shares authorized, -0- and -0- issued and outstanding, respectively at $0.001 par value; liquidation preference $-0- and $-0-, respectively		-0-			-0-
Series D preferred stock, 250,000 shares authorized, 250,000 and 250,000 issued and outstanding, respectively at $0.001 par value		250			250
Common stock, 500,000,000 shares authorized, 148,042,805 and 147,786,917 issued and outstanding, respectively, at $0.001 par value		148,044			147,788
Additional paid in capital - preferred		999,750			999,750
Additional paid in capital - common		54,124,362			53,425,956
Accumulated other comprehensive (loss)		(397,119	)		(410,505	)
Accumulated (deficit)		(72,896,491	)		(75,291,037	)

TOTAL SHAREHOLDERS' (DEFICIT)		(18,021,204	)		(21,127,798	)

TOTAL LIABILITIES AND SHAREHOLDERS' (DEFICIT)	$	7,765,847		$	8,130,350

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	For the nine months ended						For the three months ended
	September 30,						September 30,
	2017			2016			2017			2016
Revenues	$	19,420,456		$	16,449,374		$	6,490,147		$	6,627,104
Reimbursable revenues		755,344			818,036			225,766			179,307
Total revenues		20,175,800			17,267,410			6,715,913			6,806,411

Cost of goods sold		3,320,190			2,937,145			1,133,480			1,026,115
Reimbursable expenses-cost of goods sold		802,975			824,383			181,965			185,090
Total cost of goods sold		4,123,165			3,761,528			1,315,445			1,211,205

Gross margin		16,052,635			13,505,882			5,400,468			5,595,206

Operating expenses
Salaries, benefits and related taxes		9,906,293			8,341,342			3,393,915			2,897,917
Rent and occupancy expenses		841,718			800,143			292,669			299,085
Consulting services		185,222			111,284			64,488			63,284
Legal and professional fees		367,403			281,745			126,959			78,449
Travel		679,766			577,266			188,406			177,204
Telephone and internet		115,660			122,923			39,786			39,256
Selling, general and administrative		937,313			1,122,847			277,047			298,072
Bad debt expense		40,369			57,862			87,366			24,555
Depreciation expense		249,801			224,302			87,382			77,725
Amortization expense		16,455			30,405			5,580			10,152
Total operating expenses		13,340,000			11,670,119			4,563,598			3,965,699

Operating income/(loss)		2,712,635			1,835,763			836,870			1,629,507

Other income/(expense)
Interest expense, related parties		(717,782	)		(681,063	)		(252,585	)		(237,377	)
Interest expense		(342,240	)		(303,827	)		(127,488	)		(128,454	)
Interest income		589			2			3			-0-
Change in derivative liabilities		723,532			(3,016,398	)		(812,535	)		(557,562	)
Transaction gain/(loss)		19,006			(12,238	)		(3,104	)		(11,728	)
Income/(loss) before income taxes		2,395,740			(2,177,761	)		(358,839	)		694,386
Income tax (expense)		(1,194	)		(1,069	)		-0-			(1,010	)
Net income/(loss) attributable to common stockholders	$	2,394,546		$	(2,178,830	)	$	(358,839	)	$	693,376

Net income/(loss) per share
Basic	$	0.02		$	(0.01	)	$	(0.00	)	$	0.00
Diluted	$	0.02		$	(0.01	)	$	(0.00	)	$	0.00
Weighted average number of shares outstanding
Basic		147,805,410			145,257,206			147,858,566			147,686,257
Diluted		147,850,886			145,257,206			147,858,566			147,972,209

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)

(unaudited)

	For the nine months ended					For the three months ended
	September 30,					September 30,
	2017		2016			2017			2016
Net income/(loss) attributable to common stockholders	$	2,394,546	$	(2,178,830	)	$	(358,839	)	$	693,376
Other comprehensive income/(loss)
Change in foreign currency translation adjustment		13,386		(25,567	)		1,310			(7,780	)

Other comprehensive income/(loss)		13,386		(25,567	)		1,310			(7,780	)

Comprehensive income/(loss)	$	2,407,932	$	(2,204,397	)	$	(357,529	)	$	685,596

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' (DEFICIT)
FOR THE YEAR ENDED DECEMBER 31, 2016 AND THE NINE MONTHS ENDED SEPTEMBER 30, 2017
(unaudited)

	Preferred Stock													Common Stock
	5% Series A Convertible						Series D Preferred				Additional									Additional						Accumulated
	Number			$0.001			Number		$0.001		paid in			Number			$0.001			paid in						other			Total
	of shares			Par value			of shares		Par value		capital preferred			of shares			Par value			capital common			Accumulated (deficit)			comprehensive (loss)			shareholders' (deficit)
Balances at December 31, 2015		3,637,724		$	3,637			250,000	$	250	$	4,230,792			131,703,577		$	131,704		$	49,974,415		$	(75,392,917	)	$	(366,355	)	$	(21,418,474	)

Employee stock option expense																					35,046									35,046

Foreign currency translation adjustment																											(44,150	)		(44,150	)

Restricted stock issuance/(forfeiture)															360,000			360			68,040									68,400

Issuance of common stock, stock option exercise															1,100,000			1,100			128,400									129,500

Cashless issuance of common stock, stock option exercise															7,644			8			(8	)								-0-

Issuance of common stock, in exchange for Series A Preferred Stock		(3,637,724	)		(3,637	)						(3,231,042	)		14,615,696			14,616			3,220,063									-0-

Net income/(loss) for the year ended December 31, 2016		-0-			-0-			-0-		-0-		-0-			-0-			-0-			-0-			101,880			-0-			101,880

Balances at December 31, 2016		-0-			-0-			250,000		250		999,750			147,786,917			147,788			53,425,956			(75,291,037	)		(410,505	)		(21,127,798	)

Employee stock option expense																					263,679									263,679

Foreign currency translation adjustment																											13,386			13,386

Restricted stock issuance/(forfeiture)															(16,668	)		(17	)		(2,817	)								(2,834	)

Cashless issuance of common stock, stock option exercise															22,556			23			(23	)								-0-

Issuance of common stock, stock option exercise															250,000			250			35,000									35,250

Reclassification of conversion feature liability associated with convertible debt																					402,567									402,567

Net income/(loss) for the period ended September 30, 2017		-0-			-0-			-0-		-0-		-0-			-0-			-0-			-0-			2,394,546			-0-			2,394,546

Balances at September 30, 2017		-0-		$	-0-			250,000	$	250	$	999,750			148,042,805		$	148,044		$	54,124,362		$	(72,896,491	)	$	(397,119	)	$	(18,021,204	)

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

	For the nine months ended
	September 30,
	2017			2016

CASH FLOWS FROM OPERATING ACTIVITIES
Net income/(loss)	$	2,394,546		$	(2,178,830	)
Adjustment to reconcile net income/(loss) to net cash provided by/(used in) operating activities
Change in derivative liabilities		(723,532	)		3,016,398
Interest expense from derivative instruments		241,664			96,639
Employee stock compensation		467,930			168,873
Provision for doubtful accounts		40,369			57,862
Depreciation and amortization		266,256			254,707
Changes in operating assets and liabilities
Accounts receivable		(889	)		(754,545	)
Prepaid expenses		(47,519	)		(9,648	)
Other current assets		2,915			(33,558	)
Other assets		4,843			(6,326	)
Accounts payable and accrued expenses		(510,316	)		184,731
Patent settlement liability		(449,479	)		(362,921	)
Deferred revenue		(406,867	)		198,209
Net cash provided by/(used in) operating activities		1,279,921			631,591

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(212,173	)		(220,672	)
Net cash (used in) investing activities		(212,173	)		(220,672	)

CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of notes payable		(1,020,000	)		-0-
Proceeds/(repayments) from revolving line of credit		(200,000	)		(100,000	)
Proceeds from exercise of stock options		35,250			125,000
Net cash provided by/(used in) financing activities		(1,184,750	)		25,000

Effect of exchange rate changes on fixed and intangible assets		(18,125	)		(4,827	)
Effect of exchange rate changes on cash and cash equivalents		13,386			(25,567	)
Net increase/(decrease) in cash and cash equivalents		(121,741	)		405,525
Cash and cash equivalents at beginning of period		1,439,332			835,219

Cash and cash equivalents at end of period	$	1,317,591		$	1,240,744

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Income taxes	$	1,194		$	1,069
Interest	$	802,327		$	1,078,795

Non-cash transactions:
Notes payable issued in exchange for existing notes payable	$	350,000		$	7,652,500
Restricted stock issuance/(forfeiture)	$	(2,834	)	$	68,400
Promissory notes issued for accrued interest	$	-0-		$	450,000
Common stock issued in exchange for 5% Series A Preferred Stock	$	-0-		$	3,637,724
Reclassification of conversion feature liability associated with convertible debt	$	402,567		$	-0-

See accompanying summary of accounting policies and notes to unaudited condensed consolidated financial statements

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

NOTE 1:

ORGANIZATION AND NATURE OF OPERATIONS

OmniComm Systems, Inc. (“OmniComm” or the “Company”) is a healthcare technology company that provides web-based electronic data capture (“EDC”) solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations (“CROs”) and other clinical trial sponsors principally located in the United States, Europe and East Asia. Our proprietary EDC software applications; TrialMaster^®, TrialOne^®, eClinical Suite and Promasys^® (the “EDC Software”) allow clinical trial sponsors and investigative sites to securely collect, validate, transmit and analyze clinical trial data.

Our ability to compete within the EDC industry is predicated on our ability to continue enhancing and broadening the scope of solutions offered through our EDC Software and services. Our research and product development efforts are focused on developing new and complementary software solutions, as well as enhancing our existing software solutions through the addition of increased functionality. During the nine month periods ended September 30, 2017 and September 30, 2016 we spent $2,230,566 and $1,946,737, respectively, on research and product development activities, which are primarily comprised of salaries to our developers and other research and product development personnel and related costs associated with the development of our software products.

NOTE 2:

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION

The Company’s accounts include those of all its wholly-owned subsidiaries, which are more fully described in the Company’s 2016 Annual Report filed on Form 10-K with the Securities and Exchange Commission, and have been prepared in conformity with (i) accounting principles generally accepted in the United States of America; and (ii) the rules and regulations of the United States Securities and Exchange Commission. All significant intercompany accounts and transactions between the Company and its subsidiaries have been eliminated in consolidation.

UNAUDITED FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, pursuant to the rules and regulations of the Securities and Exchange Commission. Pursuant to such rules and regulations, certain financial information and footnote disclosures normally included in the consolidated financial statements have been condensed or omitted. The results for the nine month periods ended September 30, 2017 and September 30, 2016 are unaudited, but reflect all adjustments (consisting only of normally recurring adjustments) which management considers necessary for a fair presentation of operating results.

The operating results for the nine month period ended September 30, 2017 are not necessarily indicative of the results that may be expected for the year-ended December 31, 2017. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year-ended December 31, 2016.

ESTIMATES IN FINANCIAL STATEMENTS

The preparation of the unaudited condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Significant estimates incorporated in our financial statements include the recorded allowance for doubtful accounts, the estimate of the appropriate amortization period of our intangible assets, the evaluation of whether our intangible assets have suffered any impairment, the allocation of revenues under multiple-element customer contracts, royalty-based patent liabilities, the value of derivatives associated with debt issued by the Company and the valuation of any corresponding discount to the issuance of our debt. Actual results may differ from those estimates.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

Reclassifications

Certain reclassifications have been made in the 2016 financial statements to conform to the 2017 presentation. These reclassifications did not have any effect on our net income/(loss) or shareholders’ deficit.

foreign currency translation

The financial statements of the Company’s foreign subsidiaries are translated in accordance with Accounting Standards Codification (“ASC”) 830-30, Foreign Currency Matters—Translation of Financial Statements ("ASC 830-30"). The reporting currency for the Company is the U.S. dollar. The functional currency of the Company’s subsidiaries, OmniComm Europe GmbH in Germany, OmniComm Spain S.L. in Spain and OmniComm Systems B.V. in the Netherlands is the Euro. The functional currency of the Company’s subsidiary, OmniComm Ltd. in the United Kingdom, is the British Pound Sterling. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income/(loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations. We record translation gains and losses in accumulated other comprehensive income as a component of stockholders’ equity. We recorded a translation gain of $13,386 and a translation loss of $25,567 for the nine month periods ended September 30, 2017 and September 30, 2016, respectively.

REVENUE RECOGNITION POLICY

The Company derives revenues from software licenses and services of its EDC products and services which can be purchased on a stand-alone basis. License revenues are derived principally from the sale of term licenses for the following software products offered by the Company: TrialMaster, TrialOne, eClinical Suite and Promasys. Service revenues are derived principally from the Company's delivery of the hosted solutions of its TrialMaster and eClinical Suite software products, and consulting services and customer support, including training, for all of the Company's products.

The Company recognizes revenues when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the product or service has been provided to the customer; (3) the collection of fees is probable; and (4) the amount of fees to be paid by the customer is fixed or determinable.

The Company operates in one reportable segment which is the delivery of EDC Software and services to clinical trial sponsors. The Company segregates its revenues based on the activity cycle used to generate its revenues. Accordingly, revenues are currently generated through four main activities, including hosted applications, licensing, professional services and maintenance-related services.

Hosted Application Revenues

The Company offers its TrialMaster and eClinical Suite software products as hosted application solutions delivered through a standard web browser, with customer support and training services. The Company's TrialOne and Promasys solutions are presently available on a technology transfer or off-the-shelf basis. To date, hosted applications revenues have been primarily related to TrialMaster and eClinical Suite.

Revenues resulting from TrialMaster and eClinical Suite application hosting services consist of three components of services for each clinical trial. The first component is comprised of application set up, including design of electronic case report forms and edit checks, installation and server configuration of the system. The second component involves application hosting and related support services as well as billable change orders which consist of amounts billed to customers for functionality changes made. The third component involves services required to close out, or lock, the database for the clinical trial.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

Fees charged for the trial system design, set up and implementation are amortized and recognized ratably over the estimated hosting period. Work performed outside the original scope of work is contracted for separately as an additional fee and is generally recognized ratably over the remaining term of the hosting period. Fees for the first and third stages of the service are typically billed based upon milestones. Revenues earned upon completion of a contractual milestone are deferred and recognized over the estimated remaining hosting period. Fees for application hosting and related services in the second stage are generally billed monthly or quarterly in advance. Revenues resulting from hosting services for the eClinical Suite products consist of installation and server configuration, application hosting and related support services. Revenues are recognized ratably over the period of the service.

Licensing Revenues

The Company's software license revenues are earned from the sale of off-the-shelf software. From time to time a client might require significant modification or customization subsequent to delivery to the customer. The Company generally enters into software term licenses for its EDC Software products with its customers for three to five year periods, although customers have entered into both longer and shorter term license agreements. These arrangements typically include multiple elements: software license, consulting services and customer support. The Company bills its customers in accordance with the terms of the underlying contract. Generally, the Company bills license fees in advance for each billing cycle of the license term, which typically is either on a quarterly or annual basis. Payment terms are generally net 30 days.

The Company has sold perpetual licenses for EDC Software products in certain situations to existing customers with the option to purchase customer support, and may, in the future, do so for new customers based on customer requirements or market conditions. The Company has established vendor specific objective evidence of fair value for the customer support. Accordingly, license revenues are recognized upon delivery of the software and when all other revenue recognition criteria are met. Customer support revenues are recognized ratably over the term of the underlying support arrangement. The Company generates customer support and maintenance revenues from its perpetual license customer base.

Professional Services

The Company may also enter into arrangements to provide consulting services separate from a license arrangement. In these situations, revenue is recognized on a time-and-materials basis. Professional services can be deemed to be as essential to the functionality of the software at inception and typically are for initial trial configuration, implementation planning, loading of software, building simple interfaces, running test data and documentation of procedures. Subsequent additions or extensions to license terms do not generally include additional professional services.

Maintenance Revenues

Maintenance includes telephone-based help desk support and software maintenance, including updates to the software through new software version releases. The Company generally bundles customer support with the software license for the entire term of the arrangement. As a result, the Company generally recognizes revenues for both maintenance and software licenses ratably over the term of the software license and support arrangement. The Company allocates the revenues recognized for these arrangements to the different elements based on management's estimate of the relative fair value of each element. The Company generally invoices each of the elements based on separately quoted amounts and thus has a fairly accurate estimate of the relative fair values of each of the invoiced revenue elements.

Pass-through Revenue and Expense

The Company accounts for pass-through revenue and expense (reimbursable revenue and reimbursable expense) in accordance with ASC 605-45, Principal Agent Considerations (“ASC 605-45”). In accordance with ASC 605-45 these amounts are recorded as revenue in the statement of operations with a corresponding expense recorded in cost of goods sold. Pass-through revenues and expenses include amounts associated with third-party services provided to our customers by our service and product partners. These third-party services are primarily comprised of Interactive Voice and Web Response software services (IVR and IWR), travel and shipping that are incurred on our clients’ behalf.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

The fees associated with each business activity for the nine month periods ended September 30, 2017 and September 30, 2016, respectively, are:

	For the nine months ended
Revenue activity	September 30, 2017		September 30, 2016
Set-up fees	$	3,948,687	$	4,891,415
Change orders		1,054,288		932,130
Maintenance		3,749,897		3,556,114
Software licenses		7,951,228		4,204,527
Professional services		2,526,379		2,909,143
Hosting		945,321		774,081
Total	$	20,175,800	$	17,267,410

COST OF GOODS SOLD

Cost of goods sold primarily consists of costs related to hosting, maintaining and supporting the Company’s application suite and delivering professional services and support. These costs include salaries, benefits and bonuses for the Company’s professional services staff. Cost of goods sold also includes outside service provider costs. Cost of goods sold is expensed as incurred.

CASH AND CASH EQUIVALENTS

Cash equivalents consist of highly liquid, short-term investments with maturities of 90 days or less. The carrying amount reported in the accompanying consolidated balance sheets approximates fair value.

ACCOUNTS RECEIVABLE

Accounts receivable are judged as to collectability by management and an allowance for bad debts is established as necessary. The allowance is based on an evaluation of the collectability of accounts receivable and prior bad debt experience. The Company had recorded an allowance for uncollectible accounts receivable of $220,182 as of September 30, 2017 and $179,813 as of December 31, 2016.

The following table summarizes activity in the Company's allowance for doubtful accounts for the nine month period ended September 30, 2017 and the year ended December 31, 2016.

	September 30, 2017		December 31, 2016
Beginning of period	$	179,813	$	116,834
Bad debt expense		40,369		132,767
Write-offs		-0-		(69,788	)
End of period	$	220,182	$	179,813

Concentration of Credit Risk

Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of September 30, 2017, $902,864 was deposited in excess of FDIC-insured limits. Management believes the risk in these situations to be minimal.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

Except as follows, the Company has no significant off-balance-sheet risk or credit risk concentrations. Financial instruments that subject the Company to potential credit risks are principally cash equivalents and accounts receivable. Concentrated credit risk with respect to accounts receivable is limited to creditworthy customers. The Company's customers are principally located in the United States, Europe and East Asia. The Company is directly affected by the overall financial condition of the pharmaceutical, biotechnology and medical device industries and management believes that credit risk exists and that any credit risk the Company faces has been adequately reserved for as of September 30, 2017. The Company maintains an allowance for doubtful accounts based on accounts past due according to contractual terms and historical collection experience. Actual losses, when incurred, are charged to the allowance. The Company's losses related to collection of accounts receivable have consistently been within management's expectations. As of September 30, 2017, the Company believes no additional credit risk exists beyond the amounts provided for in our allowance for uncollectible accounts. The Company evaluates its allowance for uncollectable accounts on a quarterly basis based on a specific review of receivable aging and the period that any receivables are beyond the standard payment terms. The Company does not require collateral from its customers in order to mitigate credit risk.

One customer accounted for 10% of our revenues during the nine month period ended September 30, 2017 or approximately $2,021,000. One customer accounted for 18% of our revenues during the nine month period ended September 30, 2016 or approximately $3,028,000. The following table summarizes the number of customers who individually comprise greater than 10% of total revenue and/or total accounts receivable and their aggregate percentage of the Company's total revenue and gross accounts receivable for the nine month periods ended September 30, 2017 and September 30, 2016 and the year ended December 31, 2016.

	Revenues				Accounts receivable
For the period ended	Number of customers		Percentage of total revenues		Number of customers		Percentage of accounts receivable
September 30, 2017		1		10%		2		38%
December 31, 2016		1		16%		2		21%
September 30, 2016		1		18%		1		11%

The table below provides revenues from European customers for the nine month periods ended September 30, 2017 and September 30, 2016.

European revenue

For the nine months ended

September 30, 2017

September 30, 2016

European revenues

% of Total revenues

European revenues

% of Total revenues

$2,514,601

12%

$1,883,940

11%

The Company serves all of its hosting customers from third-party web hosting facilities located in the United States. The Company does not control the operation of these facilities and they are vulnerable to damage or interruption. The Company maintains redundant systems that can be used to provide service in the event the third-party web hosting facilities become unavailable, although in such circumstances, the Company's service may be interrupted during the transition.

PROPERTY AND EQUIPMENT

Property and equipment are recorded at cost. Additions and betterments are capitalized; maintenance and repairs are expensed as incurred. Depreciation is calculated using the straight-line method over the asset’s estimated useful life, which is 5 years for leasehold improvements, computers, equipment and furniture and 3 years for software. Gains or losses on disposal are charged to operations.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

ASSET IMPAIRMENT

Acquisitions and Intangible Assets

We account for acquisitions in accordance with ASC 805, Business Combinations (“ASC 805”) and ASC 350, Intangibles- Goodwill and Other (“ASC 350”). The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of a business acquisition. Our consolidated financial statements and results of operations reflect an acquired business from the completion date of an acquisition.

The judgments that we make in determining the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact net income in periods following an asset acquisition. We generally use either the income, cost or market approach to aid in our conclusions of such fair values and asset lives. The income approach presumes that the value of an asset can be estimated by the net economic benefit to be received over the life of the asset, discounted to present value. The cost approach presumes that an investor would pay no more for an asset than its replacement or reproduction cost. The market approach estimates value based on what other participants in the market have paid for reasonably similar assets. Although each valuation approach is considered in valuing the assets acquired, the approach ultimately selected is based on the characteristics of the asset and the availability of information.

Long-lived Assets

We review long-lived assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment has occurred typically requires various estimates and assumptions, including determining which cash flows are directly related to the potentially impaired asset, the useful life over which cash flows will occur, their amount and the asset’s residual value, if any. In turn, measurement of an impairment loss requires a determination of fair value, which is based on the best information available. We use quoted market prices when available and independent appraisals and management estimates of future operating cash flows, as appropriate, to determine fair value.

FAIR VALUE MEASUREMENT

OmniComm’s capital structure includes the use of warrants and convertible debt features that are classified as derivative financial instruments. Derivative financial instruments are recognized as either assets or liabilities and are measured at fair value under ASC 815, Derivatives and Hedging (“ASC 815”). ASC 815 requires that changes in the fair value of derivative financial instruments with no hedging designation be recognized as gains/(losses) in the earnings statement. The fair value measurement is determined in accordance with ASC 820, Fair Value Measurements and Disclosures (“ASC 820”).

DEFERRED REVENUE

Deferred revenue represents cash advances and amounts in accounts receivable as of the balance sheet date received in excess of revenue earned on on-going contracts. Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones. In the event of contract cancellation, the Company is generally entitled to payment for all work performed through the point of cancellation. As of September 30, 2017, the Company had $9,132,363 in deferred revenues relating to contracts for services to be performed over periods ranging from one month to 5 years. The Company had $7,131,466 in deferred revenues that are expected to be recognized in the next twelve fiscal months.

ADVERTISING

Advertising costs are expensed as incurred. Advertising costs were $528,778 and $563,803 for the nine month periods ended September 30, 2017 and September 30, 2016, respectively, and are included under selling, general and administrative expenses in our unaudited condensed consolidated financial statements.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

RESEARCH AND PRODUCT DEVELOPMENT EXPENSES

Software development costs are expensed as incurred. ASC 985-20, Software Industry Costs of Software to Be Sold, Leased or Marketed (“ASC 985-20”), requires the capitalization of certain development costs of software to be sold once technological feasibility is established, which the Company defines as completion to the point of marketability. The capitalized cost is then amortized on a straight-line basis over the estimated product life. To date, the period between achieving technological feasibility and the general availability of such software has been short and software development costs qualifying for capitalization have been immaterial. Accordingly, the Company has not capitalized any software development costs under ASC 985-20. During the nine month periods ended September 30, 2017 and September 30, 2016 we spent $2,230,566 and $1,946,737, respectively, on research and product development activities, which include costs associated with the development of our software products and services for our clients’ projects and which are primarily comprised of salaries and related expenses for our software developers and consulting fees paid to third-party consultants. Research and product development costs are primarily included under Salaries, benefits and related taxes in our Statement of Operations.

EQUITY INCENTIVE PLANS

The OmniComm Systems, Inc. 2016 Equity Incentive Plan (the “2016 Plan”) was approved at our Annual Meeting of Shareholders on June 16, 2016. The 2016 Plan initially provides for the issuance of up to 10,000,000 shares of our common stock. In addition, the number of shares of common stock available for issuance under the 2016 Plan automatically increases on January 1st of each year for a period of nine (9) years commencing on January 1, 2017 and ending on (and including) January 1, 2025, in an amount equal to five percent (5%) of the total number of shares authorized under the 2016 Plan. As of September 30, 2017 10,500,000 shares of our common stock were authorized for issuance under the 2016 Plan.

The predecessor plan, the OmniComm Systems, Inc. 2009 Equity Incentive Plan (the “2009 Plan”) was approved at our Annual Meeting of Shareholders on July 10, 2009 and terminated on June 16, 2016 upon the approval of the 2016 Plan. The 2009 Plan provided for the issuance of up to 7,500,000 shares to employees, directors and key consultants. The 2016 and 2009 Plans are more fully described in “Note 13, Equity Incentive Plans”.

The Company accounts for its employee equity incentive plans under ASC 718, Compensation – Stock Compensation, (“ASC 718”) which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. The Company currently uses the Black Scholes option pricing model to determine grant date fair value.

EARNINGS PER SHARE

The Company accounts for Earnings per Share using ASC 260, Earnings per Share, (“ASC 260”). Unlike diluted earnings per share basic earnings per share excludes any dilutive effects of options, warrants and convertible securities.

INCOME TAXES

The Company accounts for income taxes in accordance with ASC 740, Income Taxes (“ASC 740”). ASC 740 has as its basic objective the recognition of current and deferred income tax assets and liabilities based upon all events that have been recognized in the financial statements as measured by the provisions of the enacted tax laws.

Valuation allowances are established, when necessary, to reduce deferred tax assets to the estimated amount to be realized. Income tax expense represents the tax payable for the current period and the change during the period in the deferred tax assets and liabilities.

IMPACT OF NEW ACCOUNTING STANDARDS

During the first nine months of 2017, we adopted the following new accounting pronouncements:

In July 2017, The Financial Accounting Standards Board issued Accounting Standards Update 2017-11 “Earnings per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815)” (“ASU 2017-11”) to address narrow issues identified as a result of the complexity associated with applying generally accepted accounting principles (GAAP) for certain financial instruments with characteristics of liabilities and equity. Part I of the amendment change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The amendments also clarify existing disclosure requirements for equity-classified instruments. Part II of the update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. Part I of ASU 2017-11 is effective for public business entities for fiscal years, and interim period within those fiscal years, beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU-2017-11.

Accounting standards-setting organizations frequently issue new or revised accounting rules. We regularly review all new pronouncements to determine their impact, if any, on our financial statements.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

NOTE 3:

EARNINGS/(LOSS) PER SHARE

Basic earnings/(loss) per share were calculated using the weighted average number of shares outstanding of 147,805,410 and 145,257,206 for the nine month periods ended September 30, 2017 and September 30, 2016, respectively.

The outstanding share balance as of September 30, 2017 and September 30, 2016, respectively, includes -0- and 1,476,683 restricted shares that have been issued but are still at risk of forfeiture as the restrictions have not lapsed.

Antidilutive shares of 31,924,411 and 45,059,064 have been omitted from the calculation of dilutive earnings/(loss) per share for the nine month periods ended September 30, 2017 and September 30, 2016, respectively, as the shares were antidilutive. Provided below is the reconciliation between numerators and denominators of the basic and diluted earnings per shares. The table below provides a reconciliation of anti-dilutive securities outstanding as of September 30, 2017 and September 30, 2016, respectively.

Anti-dilutive security	September 30, 2017		September 30, 2016
Employee stock options		4,050,000		1,139,048
Warrants		27,020,000		27,860,000
Convertible notes		740,000		15,910,000
Shares issuable for accrued interest		114,411		150,016
Total		31,924,411		45,059,064

The employee stock options are exercisable at prices ranging from $0.17 to $0.25 per share. The exercise prices on the warrants range from $0.25 to $0.60 per share. Shares issuable upon conversion of Convertible Debentures or accrued interest have conversion prices ranging from $0.25 to $1.25 per share.

Some of the Company’s convertible debt and convertible preferred stock have an anti-dilutive effect on net income/(loss) per share and were not included in the computation of diluted earnings per share.

	For the nine months ended
	September 30, 2017						September 30, 2016
	Income/(loss)		Shares		Per-share		Income/(loss)			Shares		Per-share
	numerator		denominator		amount		numerator			denominator		amount
Basic EPS	$	2,394,546		147,805,410	$	0.02	$	(2,178,830	)		145,257,206	$	(0.01	)

Effect of dilutive securities		-0-		45,476		-0-		-0-			-0-		-0-

Diluted EPS	$	2,394,546		147,850,886	$	0.02	$	(2,178,830	)		145,257,206	$	(0.01	)

	For the three months ended
	September 30, 2017								September 30, 2016
	Income/(loss)			Shares		Per-share			Income/(loss)		Shares		Per-share
	numerator			denominator		amount			numerator		denominator		amount
Basic EPS	$	(358,839	)		147,858,566	$	(0.00	)	$	693,376		147,686,257	$	0.00

Effect of dilutive securities		-0-			-0-		-0-			-0-		285,952		-0-

Diluted EPS	$	(358,839	)		147,858,566	$	(0.00	)	$	693,376		147,972,209	$	0.00

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

NOTE 4:

PROPERTY AND EQUIPMENT, NET

Property and equipment consists of the following:

	September 30, 2017						December 31, 2016
	Cost		Accumulated depreciation		Net book value		Cost		Accumulated depreciation		Net book value		Estimated useful life (years)
Computer & office equipment	$	2,298,388	$	1,903,556	$	394,832	$	2,125,067	$	1,761,879	$	363,188		5
Leasehold improvements		118,204		97,177		21,027		114,719		89,789		24,930		5
Computer software		2,001,828		1,846,238		155,590		1,925,462		1,720,399		205,063		3
Office furniture		161,024		124,247		36,777		158,436		114,065		44,371		5
Total	$	4,579,444	$	3,971,218	$	608,226	$	4,323,684	$	3,686,132	$	637,552

Depreciation expense for the nine month periods ended September 30, 2017 and September 30, 2016 was $249,801 and $224,302, respectively.

NOTE 5:

INTANGIBLE ASSETS, NET

Intangible assets consist of the following:

	September 30, 2017						December 31, 2016
Asset	Cost		Accumulated amortization		Net book value		Cost		Accumulated amortization		Net book value		Estimated useful life (years)
eClinical Suite customer lists	$	1,392,701	$	1,392,701	$	-0-	$	1,392,701	$	1,392,701	$	-0-		3
Promasys B.V. customer lists		117,023		30,556		86,467		104,163		21,990		82,173		15
Promasys B.V. software code		72,837		57,056		15,781		72,837		46,130		26,707		5
Promasys B.V. URLs/website		59,103		59,103		-0-		52,608		52,608		-0-		3
Total	$	1,641,664	$	1,539,416	$	102,248	$	1,622,309	$	1,513,429	$	108,880

Amortization expense was $16,455 and $30,405 for the nine month periods ended September 30, 2017 and September 30, 2016, respectively.

Remaining amortization expense for the Company’s intangible assets is as follows:

2017	$	5,592
2018		19,940
2019		7,802
2020		7,802
2021		7,802
Thereafter		53,310
Total	$	102,248

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

NOTE 6:

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following:

Account	September 30, 2017		December 31, 2016
Accounts payable	$	494,633	$	697,060
Accrued payroll and related costs		806,586		886,334
Other accrued expenses		142,406		431,961
Accrued interest		169,132		107,718
Total accounts payable and accrued expenses	$	1,612,757	$	2,123,073

NOTE 7:

LINE OF CREDIT, NOTES PAYABLE AND LIQUIDITY

On March 18, 2013, the Company entered into a $2,000,000 revolving Line of Credit (“Line of Credit”) with The Northern Trust Company guaranteed by our Executive Chairman, Cornelis F. Wit. Mr. Wit receives 2.0% interest (approximately $9,500 per month) from the Company on the assets pledged for the Line of Credit. On December 18, 2013 the Company renewed the Line of Credit and increased the available balance to $4,000,000. On February 3, 2015 the Company renewed the Line of Credit and increased the available balance to $5,000,000. On April 7, 2017 the Company renewed the Line of Credit. The Line of Credit currently matures on April 7, 2020 and carries a variable interest rate based on the prime rate. At September 30, 2017, $2,500,000 was outstanding on the Line of Credit at an interest rate of 3.25%.

Our primary sources of working capital are funds from operations and borrowings under our revolving Line of Credit. In the event that the Line of Credit is called for any reason, Mr. Wit has pledged to replace the borrowing capacity under the Line of Credit with a promissory note that utilizes the same maturity date and interest rate as the Line of Credit.

To satisfy our capital requirements, we may seek additional financing. There can be no assurance that any such funding will be available to us on favorable terms or at all. If adequate funds are not available when needed, we may be required to delay, scale back or eliminate some or all of our research and product development and marketing programs. If we are successful in obtaining additional financings, the terms of such financings may have the effect of diluting or adversely affecting the holdings or the rights of the holders of our securities or result in increased interest expense in future periods.

At September 30, 2017, the Company owed $1,102,500 in notes payable all of which are unsecured. The table below provides details as to the terms and conditions of the notes payable.

				Ending		Non related party					Related party
Origination	Maturity	Interest		principal				Long					Long
date	date	rate		September 30, 2017		Current		term			Current		term
2/29/2016	4/1/2019		12%	$	400,000	$	-0-	$	-0-		$	-0-	$	400,000
6/30/2016	4/1/2020		10%		420,000		-0-		420,000			-0-		-0-
6/30/2016	4/1/2020		12%		282,500		-0-		282,500			-0-		-0-
Discount on notes payable							-0-		(310,447	)		-0-		(140,838	)
Total				$	1,102,500	$	-0-	$	392,053		$	-0-	$	259,162

At December 31, 2016, the Company owed $1,242,500 in notes payable all of which were unsecured. The table below provides details as to the terms and conditions of the notes payable.

				Ending		Non related party					Related party
Origination	Maturity	Interest		principal				Long					Long
date	date	rate		December 31, 2016		Current		term			Current		term
2/29/2016	4/1/2019		12%	$	450,000	$	-0-	$	-0-		$	-0-	$	450,000
6/30/2016	4/1/2020		10%		420,000		-0-		420,000			-0-		-0-
6/30/2016	4/1/2020		12%		372,500		-0-		372,500			-0-		-0-
Discount on notes payable							-0-		(455,285	)		-0-		(237,664	)
Total				$	1,242,500	$	-0-	$	337,215		$	-0-	$	212,336

On April 1, 2015 the Company issued a promissory note in the amount of $20,000 to our Executive Vice Chairman, Randall G. Smith ("Mr. Smith"), in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2018. The note was repaid in full on December 14, 2016.

On February 29, 2016, the Company issued a promissory note in the principal amount of $450,000 and warrants to purchase 1,800,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2019 to our Executive Chairman, Cornelis F. Wit (“Mr. Wit”), in exchange for accrued interest in the amount of $450,000. The note carries an interest rate of 12% per annum and has a maturity date of April 1, 2019. On December 5, 2016 Mr. Wit sold 1,000,000 of the warrants to an employee of the Company. On August 31, 2017 the Company repaid $50,000 to Mr. Wit.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

The February 29, 2016 issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of $325,689 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore $124,311. The warrant liability (discount) will be amortized over the 37 month duration of the note payable. The Company will continue to perform a fair value calculation quarterly on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.

On June 30, 2016, the Company issued promissory notes in the principal amount of $372,500 and warrants to purchase 1,490,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2020 to two investors including our former Director, Mr. van Kesteren, in exchange for existing promissory notes in the same amount. The notes carry an interest rate of 12% per annum and have a maturity date of April 1, 2020. On August 31, 2017 the Company repaid the $90,000 note payable to Mr. van Kesteren.

The June 30, 2016 issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of $246,921 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore $125,579. The warrant liability (discount) will be amortized over the 45 month duration of the note payables. The Company will continue to perform a fair value calculation quarterly on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.

On June 30, 2016, the Company issued promissory notes in the principal amount of $420,000 and warrants to purchase 1,680,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2020 to two investors, in exchange for existing promissory notes in the same amount. The notes carry an interest rate of 10% per annum and have a maturity date of April 1, 2020.

The June 30, 2016 issuance caused us to calculate and record a derivative liability for the warrant liability. The warrants were valued using the Black Scholes option pricing model. A value of $278,408 was calculated and allocated to the warrants and recorded as a liability to the issuance of the note payable. As a result of the liability we recorded a discount to the note payable. The carrying amount of the note at the time of issuance was therefore $141,592. The warrant liability (discount) will be amortized over the 45 month duration of the note payables. The Company will continue to perform a fair value calculation quarterly on the warrant liability and accordingly the warrant liability is increased or decreased based on the fair value calculation. The resulting increase or decrease is reflected in operations as an unrealized gain or loss on changes in derivative liabilities.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

NOTE 8:

CONVERTIBLE NOTES PAYABLE

The following table summarizes the convertible debt outstanding as of September 30, 2017.

						Carrying amount
Date of	Maturity	Interest		Principal at		Short term				Long term
issuance	date	rate		September 30, 2017		Related		Non related		Related		Non related
8/1/1999	6/30/2004		10%	$	50,000	$	-0-	$	50,000	$	-0-	$	-0-
8/29/2008	4/1/2019		10%		150,000		-0-		-0-		-0-		150,000
8/29/2008	4/1/2020		10%		1,770,000		-0-		-0-		1,770,000		-0-
12/16/2008	4/1/2020		12%		4,000,000		-0-		-0-		4,000,000		-0-
12/16/2008	4/1/2021		12%		200,000		-0-		-0-		-0-		200,000
Total				$	6,170,000	$	-0-	$	50,000	$	5,770,000	$	350,000

The following table summarizes the convertible debt outstanding as of December 31, 2016.

						Carrying amount
Date of	Maturity	Interest		Principal at		Short term				Long term
issuance	date	rate		December 31, 2016		Related		Non related		Related		Non related
8/1/1999	6/30/2004		10%	$	50,000	$	-0-	$	50,000	$	-0-	$	-0-
8/29/2008	4/1/2018		10%		150,000		-0-		-0-		-0-		150,000
8/29/2008	4/1/2020		10%		1,770,000		-0-		-0-		1,770,000		-0-
12/16/2008	4/1/2018		12%		200,000		-0-		-0-		-0-		200,000
12/16/2008	4/1/2020		12%		100,000		-0-		-0-		-0-		100,000
12/16/2008	4/1/2020		12%		4,055,000		-0-		-0-		4,055,000		-0-
9/30/2009	4/1/2018		12%		100,000		-0-		-0-		-0-		100,000
9/30/2009	4/1/2020		12%		625,000		-0-		-0-		-0-		625,000
Total				$	7,050,000	$	-0-	$	50,000	$	5,825,000	$	1,175,000

10% Convertible Notes

During 1999, the Company issued 10% Convertible Notes payable in the amount of $862,500 pursuant to a Confidential Private Placement Memorandum. There were costs of $119,625 associated with this offering. The net proceeds to the Company were $742,875. The notes bear interest at 10% annually, payable semi-annually. The notes were convertible after maturity, which was June 30, 2004, into shares of common stock of the Company at $1.25 per share. We are in default in the payment of principal and interest. As of September 30, 2017, $812,500 of the Convertible Notes had been repaid in cash or converted into 1,495,179 shares of common stock of the Company leaving an outstanding principal balance of $50,000. There was $91,949 of accrued interest at September 30, 2017.

Secured Convertible Debentures

On September 30, 2009, the Company sold an aggregate of $1,400,000 principal amount 12% Secured Convertible Debentures (the “Debentures”) and common stock purchase warrants (the “Warrants”) to purchase an aggregate of 5,600,000 shares of our common stock exercisable at a price of $0.25 per share for four years subsequent to the closing of the transaction to four accredited investors including our Executive Chairman, Cornelis F. Wit (“Mr. Wit”). The Company received net proceeds of $1,400,000. The Debentures, which bear interest at 12% per annum, matured on March 30, 2011. The Debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.25 per share.

On March 30, 2011, the Company repaid $200,000 of the outstanding principal amounts owed and extended $1,200,000 of the convertible notes until April 1, 2013, including $1,100,000 in convertible notes held by Mr. Wit. The Company also extended the expiration date of the warrants associated with the September 2009 offering.

On February 22, 2013, the Company and two holders extended $1,200,000 of the convertible notes until January 1, 2016, including $1,100,000 in convertible notes held by Mr. Wit. Mr. Wit also waived all his rights to the security interest under his $1,100,000 convertible notes. The expiration date of the warrants associated with the September 2009 offering was also extended to January 1, 2016.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

On January 31, 2015 the Company and Mr. Wit extended the maturity date of $1,100,000 of convertible debentures to Mr. Wit. The debentures carry an interest rate of 12% and have a maturity date of April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. On November 19, 2015 Mr. Wit converted $475,000 of the convertible debentures into 1,900,000 shares of our common stock. On November 19, 2015 the Company and Mr. Wit agreed to cancel the 1,900,000 warrants related to the $475,000 in convertible debentures and $475,000 of unrelated promissory notes in exchange for 1,900,000 shares of our common stock. On November 23, 2015 Mr. Wit sold the remaining $625,000 of convertible debentures and the related warrants to two unrelated non-affiliate shareholders.

On April 1, 2015 the Company and the holder extended the maturity date of $100,000 of convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018.

On June 30, 2016 the Company and two holders extended the maturity date of $625,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020.

On June 30, 2017 the Company repaid $100,000 of convertible debentures to a holder.

On August 24, 2017 the Company repaid $400,000 of convertible debentures to a holder.

On August 31, 2017 the Company repaid $225,000 of convertible debentures to a holder.

Convertible Debentures

August 2008

On August 29, 2008, the Company sold $2,270,000 of convertible debentures and warrants to purchase an aggregate of 4,540,000 shares of our common stock to four accredited investors including our Executive Chairman, Cornelis F. Wit (“Mr. Wit”), and one of our Directors. The convertible debentures, which bear interest at 10% per annum, were due on August 29, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share.

On September 30, 2009, the Company and two Affiliates of the Company extended $1,920,000 of the convertible debentures until August 29, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to August 29, 2013.

On February 22, 2013 the Company and Mr. Wit extended the maturity date of $1,770,000 of the convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.

On February 22, 2013 the Company and Mr. van Kesteren extended the maturity date of $150,000 of the convertible debentures due to our former Director, Guus van Kesteren (“Mr. van Kesteren”) to January 1, 2015. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015.

On April 21, 2014 the Company and Mr. van Kesteren, extended the maturity date of his $150,000 of convertible debentures to April 1, 2016. The expiration date of the warrants associated with the debentures was also extended to April 1, 2016. On July 31, 2014 Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of $150,000 was reclassified from Related Party to Non-Related Party.

On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017.

On June 30, 2015 the Company and Mr. van Kesteren extended the maturity date of $150,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017.

On June 30, 2016 the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

On June 30, 2016 the Company and Mr. van Kesteren extended the maturity date of $150,000 of convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018.

On June 30, 2017 the Company and Mr. van Kesteren extended the maturity date of $150,000 of convertible debentures to April 1, 2019. The expiration date of the warrants associated with the debentures was also extended to April 1, 2019.

December 2008

On December 16, 2008, the Company sold $5,075,000 of convertible debentures and warrants to purchase an aggregate of 10,150,000 shares of common stock to eleven accredited investors including our Executive Chairman, Cornelis F. Wit (“Mr. Wit”), our Chief Executive Officer and President, Stephen E. Johnson (“Mr. Johnson”), our Executive Vice Chairman, Randall G. Smith (“Mr. Smith”), our former Chief Financial Officer, Ronald T. Linares, and four of our Directors. The convertible debentures, which bear interest at 12% per annum, were due on December 16, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share.

On September 30, 2009 Affiliates of the Company extended $4,980,000 of Convertible Notes until December 16, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to December 16, 2013.

On February 22, 2013 the Company and the holders agreed to extend the maturity date of $4,505,000 of the convertible debentures including $4,475,000 due to Mr. Wit, $25,000 due to Mr. Johnson, and $5,000 due to Mr. Smith, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.

On February 27, 2013 the Company and Mr. Veatch extended the maturity date of $15,000 of convertible debentures issued to our former Director, Matthew Veatch, to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016.

On March 6, 2013, the Company and the holder agreed to extend the maturity date of $200,000 of convertible debentures to January 1, 2014. The expiration date of the warrants associated with the debentures was also extended to January 1, 2014.

On March 12, 2013, the Company and the holder agreed to extend the maturity date of $100,000 of convertible debentures to January 1, 2015. The expiration date of the warrants associated with the debentures was also extended to January 1, 2015.

In December 2013, the Company and two holders agreed to extend the maturity date of $360,000, including $160,000 due to our former Director, Guus van Kesteren (“Mr. van Kesteren”), of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On July 31, 2014 Mr. van Kesteren’s term on the Board of Directors ended. Effective on the same date, his convertible note in the amount of $160,000 was reclassified from Related Party to Non-Related Party.

On April 28, 2014 the Company and the holder extended the maturity date of $100,000 of convertible debentures to April 1, 2016. The expiration date of the warrants associated with the debentures was also extended to April 1, 2016.

On January 31, 2015 the Company and Mr. Wit extended the maturity date of $4,475,000 of convertible debentures to Mr. Wit to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. On November 19, 2015 the Company and Mr. Wit agreed to cancel $420,000 of the debentures and 1,680,000 of unrelated warrants in exchange for 1,680,000 shares of our common stock.

On April 27, 2015, the Company and the holder extended the maturity date of $200,000 of convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018.

On April 30, 2015, the Company and Mr. Johnson extended the maturity date of $25,000 of convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018. The convertible debentures were repaid in full on December 14, 2016.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

On May 1, 2015 the Company and Mr. van Kesteren extended the maturity date of $160,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017.

On May 1, 2015 the Company paid $5,000 to Mr. Smith in exchange for $5,000 of convertible debentures originally issued in December 2008.

On May 7, 2015 the Company and our former Director, Matthew Veatch, extended the maturity date of $15,000 of convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018. The convertible debentures were repaid in full on December 14, 2016.

On June 30, 2015 the Company and the holder extended the maturity date of $100,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017.

On June 30, 2016 the Company and Mr. Wit extended the maturity date of $4,055,000 of convertible debentures to Mr. Wit to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020.

On June 30, 2016 the Company and Mr. van Kesteren extended the maturity date of $160,000 of convertible debentures to April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018. The convertible debentures were repaid in full on December 14, 2016.

On June 30, 2016 the Company and the holder extended the maturity date of $100,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020.

On June 30, 2017, the Company and the holder agreed to extend the maturity date of $200,000 of convertible debentures to April 1, 2021. The expiration date of the warrants associated with the debentures was also extended to April 1, 2021.

On August 31, 2017 the Company repaid $155,000 of convertible debentures to two holders, including $55,000 that was repaid to Mr. Wit.

The principal payments required at maturity under the Company’s outstanding convertible debt at September 30, 2017 are as follows:

2017	$	50,000
2018		-0-
2019		150,000
2020		5,770,000
2021		200,000
Total	$	6,170,000

NOTE 9:

FAIR VALUE MEASUREMENT

The Company measures the fair value of its assets and liabilities under the guidance of ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), which defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. ASC 820 does not require any new fair value measurements, but its provisions apply to all other accounting pronouncements that require or permit fair value measurement.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

ASC 820 clarifies that fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based on the highest and best use of the asset or liability. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 820 requires the Company to use valuation techniques to measure fair value that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized as follows:

●

Level 1: Observable inputs such as quoted prices for identical assets or liabilities in active markets;

●

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly such as quoted prices for similar assets or liabilities or market-corroborated inputs; and

●

Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions about how market participants would price the assets or liabilities.

The valuation techniques that may be used to measure fair value are as follows:

Market approach - Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities

Income approach - Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about those future amounts, including present value techniques, option-pricing models and excess earnings methods

Cost approach - Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost)

The Company also adopted the provisions of ASC 825, Financial Instruments (“ASC 825”). ASC 825 allows companies to choose to measure eligible assets and liabilities at fair value with changes in value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to re-measure any of its existing financial assets or liabilities under the provisions of this Statement. The Company elected the fair value option for the issuance of warrants associated with the promissory notes issued in the nine month period ended September 30, 2016.

The Company’s financial assets or liabilities subject to ASC 820 as of September 30, 2017 include the conversion feature and warrant liability associated with convertible debentures issued during 2008 and 2009 and the warrants issued during 2011 and 2016 that are associated with notes payable. The conversion feature and warrants were deemed to be derivatives (the “Derivative Instruments”) since a fixed conversion price cannot be determined for either of the Derivative Instruments due to anti-dilution provisions embedded in the offering documents for the convertible debentures. The derivative instruments were not issued for risk management purposes and as such are not designated as hedging instruments under the provisions of ASC 815, Disclosures about Derivative Instruments and Hedging Activities. See Note 8 – Convertible Notes Payable.

Following is a description of the valuation methodologies used to determine the fair value of the Company’s financial liabilities including the general classification of such instruments pursuant to the valuation hierarchy.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

A summary as of September 30, 2017 of the fair value of liabilities measured at fair value on a recurring basis follows:

	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	September 30, 2017		(Level 1)		(Level 2)		(Level 3)
Derivatives: (1) (2)
Conversion feature liability	$	1,642,210	$	-0-	$	-0-	$	1,642,210
Warrant liability		3,556,783		-0-		-0-		3,556,783
Total of derivative liabilities	$	5,198,993	$	-0-	$	-0-	$	5,198,993

(1) The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the nine month period ended September 30, 2017

(2) The fair value at the measurement date is equal to the carrying value on the balance sheet

Significant valuation assumptions for derivative instruments at September 30, 2017
Risk free interest rate	1.23%	to	1.48%
Dividend yield		0.00%
Expected volatility	86.1%	to	115.5%
Expected life (range in years)
Conversion feature liability	1.50	to	3.50
Warrant liability	0.50	to	3.50

A summary as of December 31, 2016 of the fair value of liabilities measured at fair value on a recurring basis follows:

	Fair value at		Quoted prices in active markets for identical assets/ liabilities		Significant other observable inputs		Significant unobservable inputs
	December 31, 2016		(Level 1)		(Level 2)		(Level 3)
Derivatives: (1) (2)
Conversion feature liability	$	2,325,730	$	-0-	$	-0-	$	2,325,730
Warrant liability		3,999,362		-0-		-0-		3,999,362
Total of derivative liabilities	$	6,325,092	$	-0-	$	-0-	$	6,325,092

(1) The fair value of the derivative instruments was estimated using the Income Approach and the Black Scholes option pricing model with the following assumptions for the year ended December 31, 2016

(2) The fair value at the measurement date is equal to the carrying value on the balance sheet

Significant valuation assumptions for derivative instruments at December 31, 2016
Risk free interest rate	0.82%	to	1.45%
Dividend yield		0.00%
Expected volatility	117.3%	to	143.8%
Expected life (range in years)
Conversion feature liability	1.25	to	3.25
Warrant liability	0.25	to	3.25

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

A summary as of September 30, 2017 of the fair value of assets measured at fair value on a non-recurring basis follows:

	Carrying amount		Carrying amount		Quoted prices in active markets for identical assets/liabilities		Significant other observable inputs		Significant unobservable inputs
	December 31, 2016		September 30, 2017		(Level 1)		(Level 2)		(Level 3)
Acquired assets (3)
Promasys B.V. customer list (4)	$	82,173	$	86,467	$	-0-	$	-0-	$	136,253
Promasys B.V. software code (4)		26,707		15,781		-0-		-0-		72,943
Promasys B.V. URLs/website (4)		-0-		-0-		-0-		-0-		68,814
Total	$	108,880	$	102,248	$	-0-	$	-0-	$	278,010

(3) The fair value of the acquired assets was estimated using the Income Approach with a discounted cash flow valuation methodology applied.

(4) The acquired Promasys B.V. software code, customer list and URLs/website are not measured on a recurring basis since their initial fair value has been deemed to have a finite life and is being amortized periodically. Instead the Company performs an impairment analysis on a quarterly basis in order to determine whether the carrying value of the assets reflects the fair value of the assets in a market based transaction.

A summary as of December 31, 2016 of the fair value of assets measured at fair value on a non-recurring basis follows:

	Carrying amount		Carrying amount		Quoted prices in active markets for identical assets/liabilities		Significant other observable inputs		Significant unobservable inputs
	December 31, 2015		December 31, 2016		(Level 1)		(Level 2)		(Level 3)
Acquired assets (3)
Promasys B.V. customer list (4)	$	92,444	$	82,173	$	-0-	$	-0-	$	136,253
Promasys B.V. software code (4)		41,274		26,707		-0-		-0-		72,943
Promasys B.V. URLs/website (4)		15,159		-0-		-0-		-0-		68,814
Total	$	148,877	$	108,880	$	-0-	$	-0-	$	278,010

(3) The fair value of the acquired assets was estimated using the Income Approach with a discounted cash flow valuation methodology applied.

Other identifiable intangible assets, which are subject to amortization, are being amortized using the straight-line method over their estimated useful lives ranging from 3 to 15 years. The Impairment or Disposal of Long-Lived Asset subsection of ASC 360, Property, Plant and Equipment requires us to test the recoverability of long-lived assets, including identifiable intangible assets with definite lives, whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. In testing for potential impairment, if the carrying value of the asset group exceeds the expected undiscounted cash flows, we must then determine the amount by which the fair value of those assets exceeds the carrying value and determine the amount of impairment, if any.

The table below presents the unrealized gains/(losses) for the nine month periods ended September 30, 2017 and September 30, 2016.

	Other income/(expense)
	For the nine months ended
	September 30, 2017		September 30, 2016
The net amount of gains/(losses) for the period included in earnings attributable to the unrealized and realized gain/(losses) from changes in derivative liabilities at the reporting date	$	723,532	$	(3,016,398	)

Total unrealized and realized gains/(losses) included in earnings	$	723,532	$	(3,016,398	)

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

The tables below set forth a summary of changes in fair value of the Company’s Level 3 financial liabilities at fair value for the nine month period ended September 30, 2017 and the year ended December 31, 2016. The tables reflect changes for all financial liabilities at fair value categorized as Level 3 as of September 30, 2017 and December 31, 2016.

	Level 3 financial liabilities at fair value
								Net			Reclassification
								purchases,			of conversion
For the nine	Balance,							issuances			feature liability	Balance,
months ended	beginning			Net realized		Net unrealized		and		associated with		end
September 30, 2017	of year			gains/(losses)		gains/(losses)		settlements		convertible debt		of period
Derivatives:
Conversion feature liability	$	(2,325,730	)	$	48,375	$	232,578	$	-0-	$	402,567	$	(1,642,210	)
Warrant liability		(3,999,362	)		-0-		442,579		-0-		-0-		(3,556,783	)
Total of derivative liabilities	$	(6,325,092	)	$	48,375	$	675,157	$	-0-	$	402,567	$	(5,198,993	)

	Level 3 financial liabilities at fair value
									Net
									purchases,
	Balance,								issuances					Balance,
For the year ended	beginning			Net realized		Net unrealized			and			Net transfers		end
December 31, 2016	of year			gains/(losses)		gains/(losses)			settlements			in and/or out		of year
Derivatives:
Conversion feature liability	$	(901,243	)	$	29,108	$	(1,453,595	)	$	-0-		$	-0-	$	(2,325,730	)
Warrant liability		(1,914,923	)		-0-		(1,233,423	)		(851,016	)		-0-		(3,999,362	)
Total of derivative liabilities	$	(2,816,166	)	$	29,108	$	(2,687,018	)	$	(851,016	)	$	-0-	$	(6,325,092	)

NOTE 10:

COMMITMENTS AND CONTINGENCIES

The Company currently leases office space under operating leases for its office locations and has operating leases related to server and network co-location and disaster recovery for its operations. The minimum future lease payments required under the Company’s operating leases at September 30, 2017 are as follows:

2017	$	203,132
2018		650,435
2019		475,233
2020		338,976
2021		269,962
Thereafter		310,550
Total	$	2,248,288

In addition to annual base rental payments, the Company pays for the operating expenses associated with its leased office space and is responsible for any escalation in operating expenses as determined in the leases. Rent expense was $841,718 and $800,143 for the nine month periods ended September 30, 2017 and September 30, 2016, respectively.

The Company’s Fort Lauderdale, Florida corporate office lease expires in February 2023. The Company’s lease on its New Jersey field office expires in March 2021. The Company currently operates its wholly-owned subsidiary, OmniComm Ltd., in the United Kingdom under the terms of a lease that expires in September 2020. The Company currently operates its wholly-owned subsidiary, OmniComm Europe, GmbH, in Germany under the terms of a lease that expires in July 2018. The Company currently operates its wholly-owned subsidiary, OmniComm Systems B.V, in the Netherlands under the terms of a lease that expires in October 2018.

LEGAL PROCEEDINGS

From time to time the Company may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of September 30, 2017, there were no pending legal proceedings to which the Company or its subsidiaries are a party or to which any of its property is subject that could reasonably be expected to have a material effect on the results of our operations.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

PATENT LITIGATION SETTLEMENT

Effective April 9, 2009, we entered into a Settlement and License Agreement with DataSci, LLC (“DataSci”). DataSci granted us a worldwide, non-exclusive non-transferable right and license under the Licensed Patent and the right to sublicense TrialMaster on a Technology Transfer and Technology Transition basis. Under the terms of the Settlement and License Agreement, as amended, we are obligated to pay royalties quarterly for sales of Licensed Products, as defined therein, from January 1, 2009 until the termination of the Settlement and License Agreement on December 31, 2017 equal to two percent (2%) of OmniComm’s annual Gross Revenues or, alternatively, the annual minimum royalty payment(s), whichever is greater. In addition to the payment of royalties, the Settlement and Licensing Agreement imposes certain obligations on us including commercialization, certain sublicensing, other payments, insurance, and confidentiality. In addition and as a license fee for past use of the Licensed Patent which may have occurred prior to the effective date of the Settlement and Licensing Agreement, we issued a warrant to DataSci to purchase 1,000,000 shares of our common stock at an exercise price of $.01 per share. The Settlement and Licensing Agreement provides that upon the expiration date of the warrant, at DataSci’s sole discretion, DataSci shall exercise its option under the warrant or licensee shall pay DataSci $300,000. The warrant is exercisable commencing on the second anniversary of the Settlement and Licensing Agreement, April 2, 2011, through the expiration date of the warrant, on the termination date of the Settlement and Licensing Agreement on December 31, 2017.

On June 23, 2009, we entered into an agreement to acquire the EDC assets of eResearch Technology. Concurrent with the consummation of that transaction we entered into the First Amendment to Settlement and Licensing Agreement with DataSci, (i) to include the eResearch Technology EDC assets acquired within the definition of Licensed Products, and as such subject to the royalty payment(s), under and in accordance with the Settlement and Licensing Agreement, and (ii) provide a release by DataSci of any and all claims of infringement of the Licensed Patent in connection with the eResearch Technology EDC assets acquired which may have occurred prior to the effective date of the First Amendment to Settlement and Licensing Agreement for an aggregate amount of $300,000.

The remaining minimum royalty payments per year are as follows:

2017		$	225,000
Total		$	225,000

During the nine month periods ended September 30, 2017 and September 30, 2016 the Company recorded a charge to earnings of ($111,979) and $74,579 respectively, which amounts represent (i) the amount of additional license expense incurred above the stipulated minimum in the DataSci Settlement and License Agreement during the nine month periods ended September 30, 2017 and September 30, 2016 and (ii) the accretion of the difference between the total stipulated annual minimum royalty payments and the recorded present value accrual of the annual minimum royalty payments.

EMPLOYMENT AGREEMENTS

We have employment agreements in place with the following members of our executive management team:

Cornelis F. Wit, Executive Chairman

Randall G. Smith, Executive Vice Chairman

Stephen E. Johnson, Chief Executive Officer and President

Thomas E. Vickers, Chief Financial Officer

The employment agreements provide, among other things, for participation in employee benefits available to employees and executives. Each of the agreements will renew for successive one-year terms unless the agreement is expressly terminated by either the employee or the Company prior to the end of the then current term as provided for in the employment agreement. Under the terms of the agreement, we may terminate the employee’s employment upon 30 or 60 days notice of a material breach and the employee may terminate the agreement under the same terms and conditions. The employment agreements contain non-disclosure provisions, as well as non-compete clauses. The agreements for Mr. Smith, Mr. Johnson and Mr. Vickers contain severance provisions which entitles the employee to severance pay equal to one (1) year's salary and benefits in the event of the employee's termination by the Company for any reason other than for cause, as described in the employment agreement, or termination by the employee pursuant to a material breach of the agreement by the Company.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

NOTE 11:

RELATED PARTY TRANSACTIONS

On April 1, 2015 the Company issued a promissory note in the amount of $20,000 to our Executive Vice Chairman, Randall G. Smith (“Mr. Smith”), in exchange for an existing promissory note in the same amount. The promissory note carries an interest rate of 12% and has a maturity date of April 1, 2018. The note was repaid in full on December 14, 2016.

On April 30, 2015, the Company and Stephen E. Johnson, our Chief Executive Officer and President (“Mr. Johnson”) extended the maturity date of $25,000 of convertible debentures to Mr. Johnson, originally issued in December 2008. The debentures carry an interest rate of 12% and have a maturity date of April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018. The convertible debentures were repaid in full on December 14, 2016.

As of September 30, 2017, we have an aggregate of $5,770,000 of convertible debentures and $400,000 of promissory notes outstanding to our Executive Chairman, Cornelis F. Wit (“Mr. Wit”), and have issued certain warrants to Mr. Wit, as follows:

●

In June 2008, Mr. Wit invested $510,000 in convertible notes. On August 29, 2008, Mr. Wit converted the $510,000 and invested an additional $1,260,000 in a private placement of convertible debentures and warrants to purchase 3,540,000 shares of our common stock. The convertible debentures, which bear interest at 10% per annum, were due on August 29, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, the Company and Mr. Wit extended the $1,770,000 of convertible debentures until August 29, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to August 29, 2013.On February 22, 2013, the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. On June 30, 2016 the Company and Mr. Wit extended the maturity date of the $1,770,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020.

●

In February 2008, Mr. Wit invested $150,000 in promissory notes and from September 2008 to December 2008, Mr. Wit invested $4,200,000 in convertible notes. On December 16, 2008, Mr. Wit converted the $4,350,000 into a private placement of convertible debentures and warrants to purchase 8,700,000 shares of our common stock. The convertible debentures, which bear interest at 12% per annum, were due on December 16, 2010. The convertible debentures are convertible at any time at the option of the holder into shares of our common stock based upon a conversion rate of $0.50 per share. On September 30, 2009, the Company and Mr. Wit extended the $4,350,000 of convertible debentures until December 16, 2013 in accordance with the terms of a Secured Convertible Debenture issued on that date. The expiration date of the warrants associated with the debentures was also extended to December 16, 2013. In a private transaction on October 16, 2012, Mr. Wit purchased $125,000 of the December 2008 convertible debentures and the related 250,000 warrants from Mr. Ronald Linares, the Company’s former Chief Financial Officer. On February 22, 2013, the Company and Mr. Wit extended the maturity date of the $4,475,000 of convertible debentures to January 1, 2016. The expiration date of the warrants associated with the debentures was also extended to January 1, 2016. On January 31, 2015 the Company and Mr. Wit extended the maturity date of the $4,475,000 of convertible debentures to April 1, 2017. The expiration date of the warrants associated with the debentures was also extended to April 1, 2017. On November 19, 2015 the Company and Mr. Wit agreed to cancel $420,000 of the debentures and 1,680,000 of unrelated warrants in exchange for 1,680,000 shares of our common stock. On June 30, 2016 the Company and Mr. Wit extended the maturity date of the $4,055,000 of convertible debentures to April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020. On August 31, 2017 the Company repaid $55,000 to Mr. Wit.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

●

On February 29, 2016, the Company issued a promissory note in the principal amount of $450,000 and warrants to purchase 1,800,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2019 to Mr. Wit in exchange for accrued interest in the amount of $450,000. The note carries an interest rate of 12% per annum and has a maturity date of April 1, 2019. On Aug 31, 2017 the Company repaid $50,000 to Mr. Wit.

For the nine month periods ended September 30, 2017 and September 30, 2016 we incurred $717,782 and $681,063, respectively, in interest expense payable to related parties.

NOTE 12:

STOCKHOLDERS’ (DEFICIT)

Our authorized capital stock consists of 500,000,000 shares of common stock, $.001 par value per share, and 10,000,000 shares of preferred stock, par value $.001 per share, of which 5,000,000 shares have been designated as 5% Series A Preferred Stock, 230,000 shares have been designated as Series B Preferred Stock, 747,500 shares have been designated as Series C Preferred Stock and 250,000 shares have been designated as Series D Preferred Stock.

At the 2016 Annual Meeting of Stockholders the proposed amendment to the Company’s Certificate of Incorporation to increase the authorized number of shares of common stock by 250,000,000 shares to an aggregate of 500,000,000 shares received an affirmative vote from the holders of a majority of the outstanding shares of Voting Securities and an affirmative vote from the holders of a majority of the outstanding shares of common stock. Based on the votes received, the proposed amendment was approved and the number of authorized shares of common stock of the Company was increased from 250,000,000 shares to 500,000,000 shares.

As of September 30, 2017 we had the following outstanding securities:

o 148,042,805 shares of common stock issued and outstanding;

o 27,020,000 warrants issued and outstanding to purchase shares of our common stock;

o 4,550,000 options issued and outstanding to purchase shares of our common stock;

o 250,000 share of our Series D Preferred Stock issued and outstanding; and

o $6,170,000 principal amount Convertible Debentures convertible into 12,280,000 shares of common stock.

Common Stock

Holders of common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of our voting securities do not have cumulative voting rights. Holders of common stock are entitled to share in all dividends that the Board of Directors, in its discretion, declares from legally available funds. In the event of our liquidation, dissolution or winding up each outstanding share of common stock entitles its holder to participate in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock.

Holders of common stock have no conversion, preemptive or other subscription rights, and there are no redemption provisions for the common stock. The rights of the holders of common stock are subject to any rights that may be fixed for holders of preferred stock, when and if any preferred stock is outstanding. All outstanding shares of common stock are duly authorized, validly issued, fully paid and non-assessable.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

Preferred Stock

Our Board of Directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. In addition, the Board of Directors may fix and determine all privileges and rights of the authorized preferred stock series including:

o dividend and liquidation preferences;

o voting rights;

o conversion privileges; and

o redemption terms.

Our Board of Directors may authorize the issuance of preferred stock which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our Board of Directors can fix limitations and restrictions, if any, upon the payment of dividends on our common stock to be effective while any shares of preferred stock are outstanding.

During the period from December 2015 through April 2016 all 5% Series A Preferred Stock shareholders accepted the Company’s Exchange Offer and converted a total of 4,125,224 Series A preferred shares into 16,565,696 common shares.

The following table presents the cumulative arrearage of undeclared dividends by class of preferred stock as of September 30, 2017 and September 30, 2016, respectively, and the per share amount by class of preferred stock.

	Cumulative arrearage as of				Cumulative arrearage per share as of
	September 30,				September 30,
Series of preferred stock	2017		2016		2017		2016

Series A	$	-0-	$	-0-	$	-0-	$	-0-
Series B		609,887		609,887	$	3.05	$	3.05
Series C		1,472,093		1,472,093	$	4.37	$	4.37
Total preferred stock arrearage	$	2,081,980	$	2,081,980

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

Warrants Issued in Capital Transactions

The following tables summarize all outstanding warrants for the nine month period ended September 30, 2017 and the year ended December 31, 2016, and the related changes during these periods.

September 30, 2017									September 30, 2017
Warrants outstanding									Warrants exercisable
					Weighted average
Range of exercise price			Number outstanding		remaining contractual life		Weighted average exercise price		Number exercisable		Weighted average exercise price
$0.25	–	$0.60		27,020,000		2.09	$	0.42		27,020,000	$	0.42

December 31, 2016									December 31, 2016
Warrants outstanding									Warrants exercisable
					Weighted average
Range of exercise price			Number outstanding		remaining contractual life		Weighted average exercise price		Number exercisable		Weighted average exercise price
$0.25	–	$0.60		27,860,000		2.71	$	0.42		27,860,000	$	0.42

Warrants
Balance at December 31, 2015	22,900,000
Issued	4,970,000
Exercised	-0-
Expired/forfeited	(10,000	)
Balance at December 31, 2016	27,860,000
Issued	-0-
Exercised	-0-
Expired/forfeited	(840,000	)
Balance at September 30, 2017	27,020,000
Warrants exercisable at September 30, 2017	27,020,000

Weighted average fair value of warrants granted during 2017	n/a

Other Comprehensive (Loss)

Due to the availability of net operating losses and related deferred tax valuations, there is no tax effect associated with any component of other comprehensive (loss). The following table lists the beginning balance, activity and ending balance of the components of accumulated other comprehensive (loss).

					Accumulated other
		Foreign currency			comprehensive
		translation			(loss)
Balance at December 31, 2015	$	(366,355	)	$	(366,355	)
2016 Activity		(44,150	)		(44,150	)
Balance at December 31, 2016		(410,505	)		(410,505	)
2017 Activity		13,386			13,386
Balance at September 30, 2017	$	(397,119	)	$	(397,119	)

NOTE 13:

EQUITY INCENTIVE PLANS

Stock Option Plans

Description of 2016 Equity Incentive Plan

In 2016, the Company’s Board of Directors and shareholders approved the OmniComm Systems, Inc. 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan provides for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. The 2016 Plan initially provides for the issuance of up to 10,000,000 shares of our common stock for issuance upon awards granted under the 2016 Plan. In addition, the number of shares of common stock available for issuance under the 2016 Plan automatically increases on January 1st of each year for a period of nine (9) years commencing on January 1, 2017 and ending on (and including) January 1, 2025, in an amount equal to five percent (5%) of the total number of shares authorized under the 2016 Plan. As of September 30, 2017 10,500,000 shares of our common stock were authorized for issuance under the 2016 Plan. Unless earlier terminated by the Board, the 2016 Plan shall terminate on June 29, 2026.

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

The maximum term for any option grant under the 2016 Plan is ten years from the date of the grant; however, options granted under the 2016 Plan will generally expire five years from the date of grant. Options granted to employees generally vest either upon grant or in two installments. The first vesting, which is equal to 50% of the granted stock options, usually occurs upon completion of one full year of employment from the date of grant and the second vesting usually occurs on the second anniversary of the date of grant. The vesting period typically begins on the date of hire for new employees and on the date of grant for existing employees. The restrictions on restricted shares granted to employees generally lapse in three equal annual installments on the anniversary of the date of grant. Any unvested stock options or restricted shares with restrictions that have not lapsed that are granted under the 2016 Plan are forfeited and expire upon termination of employment.

As of September 30, 2017, there were 4,175,000 outstanding options and -0- restricted stock shares that have been granted under the 2016 Plan. At September 30, 2017, there were 6,325,000 shares available for grant as options or other forms of share-based compensation under the 2016 Plan.

Description of 2009 Equity Incentive Plan

In 2009, the Company’s Board of Directors and shareholders approved the OmniComm Systems, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). On June 16, 2016 the 2009 Plan terminated upon the approval of the 2016 Plan. The 2009 Plan provided for granting Incentive Stock Options, Nonqualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Phantom Stock Unit Awards and Performance Share Units. Pursuant to the 2009 Plan, 7,500,000 shares of the Company’s common stock were authorized for issuance.

The maximum term for any option grant under the 2009 Plan was ten years from the date of the grant; however, options granted under the 2009 Plan generally expired five years from the date of grant. Options granted to employees generally vested either upon grant or in two installments. The first vesting, which was equal to 50% of the granted stock options, usually occurred upon completion of one full year of employment from the date of grant and the second vesting usually occurred on the second anniversary of the date of grant. The vesting period typically began on the date of hire for new employees and on the date of grant for existing employees. The restrictions on restricted shares granted to employees generally lapsed in three equal annual installments on the anniversary of the date of grant. Any unvested stock options or restricted shares with restrictions that had not lapsed that were granted under the 2009 Plan were forfeited and expired upon termination of employment.

As of September 30, 2017, there were 375,000 outstanding options and 3,876,662 restricted stock shares that have been granted under the 2009 Plan. At September 30, 2017, there were -0- shares available for grant as options or other forms of share-based compensation under the 2009 Plan.

The following table summarizes the stock option activity for the Company’s equity incentive plans:

	Number of options			Weighted average exercise price (per share)		Weighted average remaining contractual term (in years)		Aggregate intrinsic value

Outstanding at December 31, 2015		2,002,500		$	0.14		1.40	$	198,990
Granted		450,000			0.20
Exercised		(1,120,000	)		0.12
Forfeited/cancelled/expired		(107,500	)		0.29

Outstanding at December 31, 2016		1,225,000			0.17		2.62	$	83,425
Granted		3,925,000			0.25
Exercised		(300,000	)		0.13
Forfeited/cancelled/expired		(300,000	)		0.14

Outstanding at September 30, 2017		4,550,000		$	0.24		4.23	$	75,875


Vested and exercisable at September 30, 2017		400,000		$	0.19		1.67	$	27,838

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company’s closing stock price at quarter-end and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on September 30, 2017.

The total number of shares vesting and the fair value of shares vesting for the nine month periods ended September 30, 2017 and September 30, 2016, respectively, was:

Fair value of options vesting
for the nine months ended

Number of

options vested

Fair value of

options vested

September 30, 2017

62,500

12,742

September 30, 2016

162,500

33,622

Cash received for stock option exercises for the nine month periods ended September 30, 2017 and September 30, 2016 was $35,250 and $125,000, respectively. Due to the Company’s net loss position, no income tax benefit has been realized during the nine month periods ended September 30, 2017 and September 30, 2016.

The following table summarizes information concerning options outstanding at September 30, 2017:

Awards breakdown by price range at September 30, 2017
			Outstanding						Vested
Strike price range ($)			Outstanding stock options		Weighted average remaining contractual life		Weighted average outstanding strike price		Vested stock options		Weighted average remaining vested contractual life		Weighted average vested strike price
0.00	to	0.20		300,000		2.19	$	0.18		250,000		1.74	$	0.17
0.21	to	0.30		4,250,000		4.38		0.25		150,000		1.55		0.22
0.31	to	0.50		-0-		0.00		0.00		-0-		0.00		0.00
0.00	to	0.50		4,550,000		4.23	$	0.24		400,000		1.67	$	0.19

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

The following table summarizes information concerning options outstanding at December 31, 2016:

Awards breakdown by price range at December 31, 2016
			Outstanding						Vested
Strike price range ($)			Outstanding stock options		Weighted average remaining contractual life		Weighted average outstanding strike price		Vested stock options		Weighted average remaining vested contractual life		Weighted average vested strike price
0.00	to	0.20		850,000		2.15	$	0.15		625,000		1.32	$	0.14
0.21	to	0.30		375,000		3.70		0.23		112,500		1.67		0.21
0.31	to	0.50		-0-		0.00		0.00		-0-		0.00		0.00
0.00	to	0.50		1,225,000		2.62	$	0.17		737,500		1.38	$	0.15

The weighted average fair value (per share) of options granted during the nine month period ended September 30, 2017 was $0.19 and $0.19 during the nine month period ended September 30, 2016. The Black Scholes option-pricing model was utilized to calculate these values.

Basis for Fair Value Estimate of Share-Based Payments

Based on analysis of its historical volatility, the Company expects that the future volatility of its share price is likely to be similar to the historical volatility the Company experienced since the Company’s commercialization activities were initiated during the second half of 2000. The Company used a volatility calculation utilizing the Company’s own historical volatility to estimate its future volatility for purposes of valuing the share-based payments that have been granted. Actual volatility, and future changes in estimated volatility, may differ substantially from the Company’s current estimates.

The Company utilizes the historical data available regarding employee and director exercise activity to calculate an expected life of the options. The table below presents the weighted average expected life in years of options granted under the Plan as described above. The risk-free rate of the stock options is based on the U.S. Treasury yield curve in effect at the time of grant, which corresponds with the expected term of the option granted.

Below are the assumptions for the fair value of share-based payments for the nine month period ended September 30, 2017 and the year ended December 31, 2016.

	Stock option assumptions for the period ended
Stock option assumptions	September 30, 2017		December 31, 2016
Risk-free interest rate		1.48%		1.45%
Expected dividend yield		0.0%		0.0%
Expected volatility		133.1%		155.5%
Expected life of options (in years)		5		5

Table of Contents

OMNICOMM SYSTEMS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 AND SEPTEMBER 30, 2016

(unaudited)

The following table summarizes weighted average grant date fair value activity for the Company’s incentive stock plans:

	Weighted average grant date fair value
	for the nine months ended September 30,
	2017		2016
Stock options granted during the period	$	0.19	$	0.19

Stock options vested during the period	$	0.20	$	0.21

Stock options forfeited during the period	$	0.13	$	0.11

A summary of the status of the Company’s non-vested shares underlying stock options as of September 30, 2017, and changes during the nine month period ended September 30, 2017 is as follows:

	Shares underlying stock options		Weighted average grant date fair value
Nonvested shares at January 1, 2017		487,500	$	0.20

Nonvested shares at September 30, 2017		4,150,000	$	0.23

As of September 30, 2017, $545,474 of total unrecognized compensation cost related to unvested stock options is expected to be recognized over a weighted-average period of 1.6 years.

NOTE 14: SUBSEQUENT EVENTS

Subsequent to September 30, 2017 the Company repaid $200,000 on its revolving Line of Credit.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

The following information should be read in conjunction with the information contained in our unaudited condensed consolidated financial statements and notes thereto appearing elsewhere herein and other information set forth in this report.

Forward-Looking Statements

Statements contained in this Form 10-Q that are not historical fact are "forward-looking statements". These statements can often be identified by the use of forward-looking terminology such as "estimate", "project", "believe", "expect", "may", "will", "should", "intends", or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements, contained in this Form 10-Q regarding matters that are not historical facts, are only predictions and are based on information available at the time and/or management’s good faith belief with respect to future events. No assurance can be given that plans for the future will be consummated or that the future results indicated, whether expressed or implied, will be achieved. While sometimes presented with numerical specificity, these plans and projections and other forward-looking statements are based upon a variety of assumptions, which we consider reasonable, but which nevertheless may not be realized. Because of the number and range of the assumptions underlying our projections and forward-looking statements, many of which are subject to significant uncertainties and contingencies that are beyond our reasonable control, some of the assumptions inevitably will not materialize, and unanticipated events and circumstances may occur subsequent to the date of this Form 10-Q. Therefore, our actual experience and results achieved during the period covered by any particular projections or forward-looking statements may differ substantially from those projected. Consequently, the inclusion of projections and other forward-looking statements should not be regarded as a representation by us or any other person that these plans will be consummated or that estimates and projections will be realized, and actual results may vary materially. There can be no assurance that any of these expectations will be realized or that any of the forward-looking statements contained herein will prove to be accurate. Forward-looking statements speak only as of the date the statement was made. The Company does not undertake any obligation to update or revise any forward-looking statement made by it or on its behalf, whether as a result of new information, future events or otherwise.

Overview

We are a healthcare technology company that provides web based electronic data capture (“EDC”) solutions and related value-added services to pharmaceutical and biotech companies, clinical research organizations (“CROs”) and other clinical trial sponsors worldwide. Our proprietary EDC software applications: TrialMaster^®; TrialOne^®; eClinical Suite and Promasys^® (the “EDC Software”), allow clinical trial sponsors and investigative sites to securely collect, validate, transmit and analyze clinical trial data electronically (“eClinical”).

In 2017, the primary focus of our strategy includes:

●

Increasing our penetration of the Phase I trial market with our dedicated Phase I solution, TrialOne

●

Stimulating demand by providing clinical trial sponsors with high value eClinical applications and services

●

Expanding our penetration of the large pharmaceutical sponsor market

●

Broadening our suite of services and software applications on an organic research and product development basis and on a selective basis via the acquisition or licensing of complementary solutions

●

Expanding our business development efforts in Europe and East Asia to capitalize on our operational and clinical capabilities vis-à-vis our competition in those geographic markets

Our operating focus is first, to increase our sales and marketing capabilities and penetration rate and secondly, to continue developing and improving our software solutions and services to ensure our services and products remain an attractive, high-value EDC choice. Our ability to compete within the EDC and eClinical industries is predicated on our ability to continue enhancing and broadening the scope of solutions we offer. Our research and product development efforts are focused on developing new, complementary software solutions, as well as enhancing our existing software solutions through the addition of increased functionality. We spent $2,230,566 and $1,946,737 on research and product development activities during the nine months ended September 30, 2017 and September 30, 2016, respectively. The majority of these expenses represent salaries and related benefits to our developers which include the costs associated with the continued development of our EDC Software applications to meet current customer requirements and with our efforts at enhancing our suite of products by incorporating new features and services we believe will improve the products and consequently improve our market position. Our research and product development team is comprised of software programmers, engineers and related support personnel.

Table of Contents

Our clients are able to partially or completely license our EDC solutions. The licensing business model provides our clients with a more cost effective means of deploying our EDC solutions on a large-scale basis. Our licensed products, falling under the auspices of either a Tech Transition (partial transfer with some services performed by OmniComm) or Tech Transfer, allows us to broaden our potential client base, provides us with a high-margin revenue source and affords us the ability to improve our competitive position within the EDC industry.

We feel that the momentum established from new client acquisitions in 2016 and year to date 2017 and our ability to retain clients for repeat engagements provide a good operating base from which to build during the remainder of 2017. We increased the marketing and business development budget for our TrialOne product during 2016 and the first nine months of 2017 as we place increased emphasis on increasing our penetration of the Phase I market in the Unites States, Europe and East Asia. We believe that segment of the EDC market is the least penetrated and allows for the greatest potential increases in market share and in sales volumes. We expect to continue increasing the level of resources deployed in our sales and marketing efforts through the addition of sales personnel and by increasing the number of industry tradeshows and conferences that we attend. We feel that a combination of our existing infrastructure, broadened array of eClinical products and services and increased success in new client acquisition, coupled with our ability to retain our existing clients will allow us to compete effectively within the EDC market.

The nine months ended September 30, 2017 compared to the nine months ended September 30, 2016

Results of Operations

A summarized version of our results of operations for the nine months ended September 30, 2017 and September 30, 2016 is included in the table below.

Summarized Statement of Operations
For the nine months ended
September 30,
				% of						% of			$			%
	2017			Revenues			2016			Revenues			Change			Change
Total revenues	$	20,175,800					$	17,267,410					$	2,908,390			16.8	%

Total cost of goods sold		4,123,165			20.4	%		3,761,528			21.8	%		361,637			9.6	%

Gross margin		16,052,635			79.6	%		13,505,882			78.2	%		2,546,753			18.9	%

Salaries, benefits and related taxes		9,906,293			49.1	%		8,341,342			48.3	%		1,564,951			18.8	%
Rent		841,718			4.2	%		800,143			4.6	%		41,575			5.2	%
Consulting services		185,222			0.9	%		111,284			0.6	%		73,938			66.4	%
Legal and professional fees		367,403			1.8	%		281,745			1.6	%		85,658			30.4	%
Other expenses		1,102,051			5.5	%		1,012,758			5.9	%		89,293			8.8	%
Selling, general and administrative		937,313			4.6	%		1,122,847			6.5	%		(185,534	)		-16.5	%
Total operating expenses		13,340,000			66.1	%		11,670,119			67.5	%		1,669,881			14.3	%

Operating income/(loss)		2,712,635			13.4	%		1,835,763			10.6	%		876,872			47.8	%

Interest expense		(1,060,022	)		-5.3	%		(984,890	)		-5.7	%		(75,132	)		7.6	%
Interest income		589			0.0	%		2			0.0	%		587			29350.0	%
Change in derivatives		723,532			3.6	%		(3,016,398	)		-17.5	%		3,739,930			124.0	%
Transaction gain/(loss)		19,006			0.1	%		(12,238	)		-0.1	%		31,244			255.3	%

Income/(loss) before income taxes and dividends		2,395,740			11.9	%		(2,177,761	)		-12.6	%		4,573,501			210.0	%
Income tax (expense)		(1,194	)		0.0	%		(1,069	)		0.0	%		(125	)		11.7	%

Net income/(loss) attributable to common stockholders	$	2,394,546			11.9	%	$	(2,178,830	)		-12.6	%	$	4,573,376			209.9	%

Table of Contents

The table below provides a comparison of our recognized revenues for the nine months ended September 30, 2017 and September 30, 2016.

	For the nine months ended
Revenue activity	September 30, 2017				September 30, 2016				$ Change			% Change
Set-up fees	$	3,948,687	19.6	%	$	4,891,415	28.3	%	$	(942,728	)		-19.3	%
Change orders		1,054,288	5.2	%		932,130	5.4	%		122,158			13.1	%
Maintenance		3,749,897	18.6	%		3,556,114	20.6	%		193,783			5.4	%
Software licenses		7,951,228	39.4	%		4,204,527	24.4	%		3,746,701			89.1	%
Professional services		2,526,379	12.5	%		2,909,143	16.8	%		(382,764	)		-13.2	%
Hosting		945,321	4.7	%		774,081	4.5	%		171,240			22.1	%
Total	$	20,175,800	100.0	%	$	17,267,410	100.0	%	$	2,908,390			16.8	%

Overall revenue increased by $2,908,390 or 16.8% for the nine months ended September 30, 2017 compared with revenue for the nine months ended September 30, 2016. This increase is primarily the result of an increase in software licenses.

We recorded revenue of $15,184,340 including $3,948,687 from set-up fees, $4,838,537 from software licensing and $2,557,261 from maintenance revenues associated with our TrialMaster suite during the nine months ended September 30, 2017 compared with revenue of $13,036,982 that included $4,891,415 in set-up fees, $2,979,266 from software licensing and $2,294,550 in maintenance revenues during the nine months ended September 30, 2016.

We recorded $1,329,257 in revenues associated with clients using the eClinical Suite during the nine months ended September 30, 2017 compared with revenue of $1,162,276 for the nine months ended September 30, 2016. eClinical Suite revenues are primarily comprised of license subscriptions and revenues associated with our hosting and maintenance services.

We recorded $682,135 in revenues in maintenance and $188,367 from hosting activities associated with the eClinical Suite during the nine months ended September 30, 2017 compared with revenue of $820,979 from maintenance and $179,492 from hosting activities for the nine months ended September 30, 2016. Generally, these revenues are paid quarterly and are connected to hosting and client support for clients licensing the eClinical Suite.

We recorded revenue of $3,286,129 including $2,573,361 from software licensing and $261,466 from professional services for clients utilizing our TrialOne EDC software for the nine months ended September 30, 2017 compared with revenue of $2,353,213 including $996,406 from software licensing and $1,028,576 from professional services for the nine months ended September 30, 2016. We are continuing to enhance our efforts at developing our sales and marketing campaign for the TrialOne application. TrialOne revenues are primarily comprised of license subscriptions, professional services and maintenance services.

We recorded revenue of $376,074 for the nine months ended September 30, 2017 including $90,274 from software licensing and $196,950 from maintenance associated with clients utilizing the Promasys EDC solution as compared to revenue of $480,783 for the nine months ended September 30, 2016 including $131,205 from software licensing and $245,722 from maintenance.

Our TrialMaster EDC application has historically been sold on an application service provider (“ASP”) basis that provides EDC and other services such as an enterprise management suite which assists our clients in the pharmaceutical, biotechnology and medical device industries in accelerating the completion of clinical trials. During 2009 we completed the acquisition of the eResearch EDC Assets and TrialOne and in 2013 we acquired Promasys (collectively the “Acquired Software”). These software applications have historically been sold on a licensed or technology transfer basis. As we continue developing our software applications and our client relationships mature, we expect some of our clients to deploy TrialMaster on a licensed, rather than ASP hosted basis. We expect the Acquired Software applications to continue to be sold primarily on a licensed basis.

TrialMaster contracts for ASP services provide for pricing that is based on both the size and duration of the clinical trial. Size parameters include the number of case report forms used to collect data and the number of sites utilizing TrialMaster. The client will pay a trial setup fee at the beginning of a project based on the previously mentioned factors and then pay an on-going maintenance fee for the duration of the clinical trial that provides software, network and site support during the trial.

Generally, ASP contracts will range in duration from one month to several years. ASP setup fees are generally recognized in accordance with ASC 605, “Revenue Recognition”, which requires that the revenues be recognized ratably over the life of the contract. ASP maintenance fee revenues are earned and recognized monthly. Costs associated with contract revenues are recognized as incurred.

License contracts are typically sold on a subscription basis that takes into account system usage both on a data volume and system user basis. Pricing includes additional charges for consulting services associated with the installation, validation, training and deployment of our eClinical software and solutions. Licensed contracts of the eClinical Suite have historically been sold both on a term and on a perpetual license basis with hosting and maintenance charges being paid quarterly. The Company expects most licenses it sells of its software products to be sold under three to five year term licenses.

Table of Contents

Our top five customers accounted for approximately 35% of our revenues during the nine months ended September 30, 2017 and approximately 36% of our revenues during the nine months ended September 30, 2016. One customer accounted for approximately 10% of our revenues during the nine months ended September 30, 2017. One customer accounted for approximately 18% of our revenues the nine months ended September 30, 2016. The loss of any of these contracts or these customers in the future could adversely affect our results of operations.

Our international customers, who are principally located in Europe and East Asia, accounted for approximately 20% of our total revenues for the nine month period ended September 30, 2017 and approximately 17% of our total revenues for the nine months ended September 30, 2016.

One customer accounted for approximately 27% and another customer accounted for approximately 11% of our accounts receivables as of September 30, 2017. One customer accounted for approximately 11% of our accounts receivable as of September 30, 2016.

Cost of goods sold increased approximately 10% or $361,637 for the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016. Cost of goods sold were approximately 20% of revenues for the nine months ended September 30, 2017 compared to approximately 22% for the nine months ended September 30, 2016. Cost of goods sold relates primarily to (i) salaries and related benefits associated with the programmers, developers and systems analysts producing clinical trials on behalf of our clients and (ii) the costs associated with pass-through revenues (reimbursable revenues). Cost of goods sold increased during the nine months ended September 30, 2017 primarily due to an increase in salaries and related benefits. The pass-through revenue and expense primarily relate to specific work being performed for a few clients. At this time we do not expect the volume of the pass-through revenue and expense to grow significantly and therefore we do not expect any significant degradation of our gross margin.

Overall, total operating expenses increased approximately 14% for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The increase in operating expenses is primarily the result of an increase in salaries, benefits and related taxes.

Salaries and related expenses were our biggest operating expense at 74% of total operating expenses for the nine months ended September 30, 2017 compared to 71% of total operating expenses for the nine months ended September 30, 2016. Salaries and related expenses increased by approximately 19% for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The table below provides a summary of the significant components of salary and related expenses by primary cost category.

	For the nine months ended
Expense Category	September 30, 2017		September 30, 2016		$ Change			% Change
OmniComm corporate operations	$	6,815,015	$	5,751,904	$	1,063,111			18.5	%
New Jersey operations office		814,050		754,175		59,875			7.9	%
OmniComm Europe, GmbH		481,792		496,258		(14,466	)		-2.9	%
OmniComm Ltd.		655,418		531,343		124,075			23.4	%
OmniComm Spain S.L.		295,138		228,146		66,992			29.4	%
OmniComm Systems B.V.		376,950		410,643		(33,693	)		-8.2	%
Employee stock compensation		467,930		168,873		299,057			177.1	%
Total salaries and related expenses	$	9,906,293	$	8,341,342	$	1,564,951			18.8	%

As of September 30, 2017, we employed 137 employees and consultants Company-wide as follows: 64 out of our headquarters in Fort Lauderdale, Florida, 9 out of a regional operating office in Somerset, New Jersey, 26 in remote locations throughout the United States and Canada. Our wholly-owned subsidiary, OmniComm Europe, GmbH, employs 18 in Bonn, Germany. Our wholly-owned subsidiary, OmniComm Ltd., employs 12 in Southampton, England. Our wholly-owned subsidiary, OmniComm Spain, S. L. employs 2 in Barcelona, Spain. Our wholly-owned subsidiary, OmniComm Systems B.V. employs 4 in the Netherlands and 2 in Japan. We believe that relations with our employees are good. None of our employees are represented by a collective bargaining agreement.

During the nine months ended September 30, 2017 and the nine months ended September 30, 2016 we incurred $467,930 and $168,873, respectively, in salary expense in connection with ASC 718, Compensation – Stock Compensation, which establishes standards for transactions in which an entity exchanges its equity instruments services from employees. This standard requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.

Table of Contents

Rent and related expenses increased by approximately 5% during the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. The table below details the significant portions of our rent expense. Our primary data site is located at a co-location facility in Cincinnati, Ohio and we will continue utilizing this facility for the foreseeable future since it is designed to ensure 100% production system up-time and to provide system redundancy. We also utilize co-location and disaster recovery space in the Fort Lauderdale, Florida area. This facility provides us with disaster recovery and business continuity services for our operations. In 2015 we added a third co-location facility in Frankfurt, Germany. We currently lease office space in Bonn, Germany for our European subsidiary, OmniComm Europe, GmbH under a lease that expires in July 2018. We currently lease office space for a regional operating office in New Jersey under a lease that expires in March 2021. Our OmniComm Ltd. subsidiary leases office space in Southampton, UK under a lease that expires in September 2020. Our OmniComm Systems B.V. subsidiary leases office space in Leiden, the Netherlands under a lease that expires in October 2018. Our Fort Lauderdale corporate office lease expires in February 2023. The table below provides the significant components of our rent related expenses by location or subsidiary. Included in rent during the nine months ended September 30, 2017 was a decrease in expense of $2,882 in non-cash, straight line rent recorded to give effect to contractual, inflation-based rent increases in our leases compared to an increase in expense of $77,780 for the nine months ended September 30, 2016.

	For the nine months ended
Expense Category	September 30, 2017			September 30, 2016		$ Change			% Change
Corporate office	$	310,813		$	211,016	$	99,797			47.3	%
Co-location and disaster recovery facilities		379,856			355,666		24,190			6.8	%
New Jersey operations office		39,444			40,265		(821	)		-2.0	%
OmniComm Europe, GmbH		58,254			59,043		(789	)		-1.3	%
OmniComm Ltd.		43,463			45,977		(2,514	)		-5.5	%
OmniComm Spain S.L.		5,958			5,012		946			18.9	%
OmniComm Systems B.V.		6,812			5,384		1,428			26.5	%
Straight-line rent expense		(2,882	)		77,780		(80,662	)		-103.7	%
Total	$	841,718		$	800,143	$	41,575			5.2	%

Consulting services expense increased to $185,222 for the nine months ended September 30, 2017 compared with $111,284 for the nine months ended September 30, 2016. Consulting services are comprised of fees paid to consultants for help with product development and for services related to our sales and marketing efforts. Product development consulting expenses increased year over year as we utilized the services of additional consultants during the nine month period ended September 30, 2017. The table provided below provides the significant components of the expenses incurred related to consulting services.

	For the nine months ended
Expense Category	September 30, 2017		September 30, 2016		$ Change			% Change
Sales and marketing	$	56,000	$	79,500	$	(23,500	)		-29.6	%
Product development		129,222		31,784		97,438			306.6	%
Total	$	185,222	$	111,284	$	73,938			66.4	%

Legal and professional fees increased approximately 30% for the nine months ended September 30, 2017 compared with the nine months ended September 30, 2016. Professional fees include fees paid to our auditors for services rendered on a quarterly and annual basis in connection with our filings with the Securities and Exchange Commission (“SEC”) and fees paid to our attorneys in connection with representation in matters involving litigation and acquisitions or for services rendered to us related to securities and SEC related matters. The table below compares the significant components of our legal and professional fees for the nine months ended September 30, 2017 and September 30, 2016, respectively.

	For the nine months ended
Expense Category	September 30, 2017		September 30, 2016		$ Change			% Change
Financial advisory	$	52,974	$	-0-	$	52,974			n/a
Audit and related		39,777		43,963		(4,186	)		-9.5	%
Accounting services		178,588		134,781		43,807			32.5	%
Legal-employment related		21,778		17,211		4,567			26.5	%
Legal-financial related		67,122		64,810		2,312			3.6	%
General legal		7,164		20,980		(13,816	)		-65.9	%
Total	$	367,403	$	281,745	$	85,658			30.4	%

Table of Contents

Selling, general and administrative expenses (“SG&A”) decreased by $185,534 or approximately 17% for the nine months ended September 30, 2017 compared to the nine months ended September 30, 2016. SG&A expenses relate primarily to costs incurred in running our offices in Fort Lauderdale, Florida, Somerset, New Jersey, Southampton, England, Barcelona, Spain, Bonn, Germany and Leiden, the Netherlands on a day-to-day basis and other costs not directly related to other captioned items in our income statement. SG&A includes the cost of office equipment and supplies, the costs of attending conferences and seminars and other expenses incurred in the normal course of business. In 2016 we spent approximately $712,000 on marketing, sales and advertising. We expect that the 2017 marketing, sales and advertising expenses will be approximately $800,000 as we increase our attendance at tradeshows and our marketing efforts worldwide.

During the nine months ended September 30, 2017 we recognized bad debt expense of $40,369 compared to bad debt expense of $57,862 for the nine months ended September 30, 2016. This change was primarily the result of a decrease in aged receivable balances that enabled us to decrease our reserve. During the remainder of 2017 we will continue to carefully and actively manage our potential exposure to bad debt by closely monitoring our accounts receivable and proactively taking the action necessary to limit our exposure. We have been very successful in managing and collecting our outstanding accounts receivable. We believe that our current allowance for uncollectible accounts accurately reflects any accounts which may prove uncollectible during the remainder of 2017.

Interest expense was $1,060,022 for the nine months ended September 30, 2017 compared to $984,890 for the nine months ended September 30, 2016, an increase of $75,132. Interest incurred to related parties was $717,782 during the nine months ended September 30, 2017 and $681,063 for the nine months ended September 30, 2016. Included in interest expense is the accretion of discounts recorded related to financial instrument derivatives that were deemed a part of the financings we undertook in 2008 and 2009 and relating to warrants issued during 2011 and 2016. Interest expense increased year over year primarily due to the accretion of the discount from the derivatives associated with debt that was issued. The table below provides detail on the significant components of interest expense for the nine months ended September 30, 2017 and September 30, 2016.

	For the nine months ended
Debt Description	September 30, 2017		September 30, 2016		$ Change			% Change
Accretion of discount from derivatives	$	241,664	$	96,638	$	145,026			150.1	%
August 2008 convertible notes		143,605		144,131		(526	)		-0.4	%
December 2008 convertible notes		389,347		410,324		(20,977	)		-5.1	%
September 2009 secured convertible debentures		54,962		65,310		(10,348	)		-15.8	%
General interest		105,282		149,447		(44,165	)		-29.6	%
Related party notes payable		125,162		119,040		6,122			5.1	%
Total	$	1,060,022	$	984,890	$	75,132			7.6	%

We evaluate the cost of capital available to us in combination with our overall capital structure and the prevailing market conditions in deciding what financing best fulfills our short and long-term capital needs. Given the overall economic climate and in particular the difficulties nano-cap companies have experienced in obtaining financing, we believe the structure and terms of the transactions we entered into during 2016 and 2017 were obtained at the best terms available to the Company.

We record unrealized gains/losses related to changes in our derivative liabilities associated with the issuance of convertible debt that occurred during 2008 and 2009 and warrants associated with promissory notes issued in 2011 and 2016. We recorded a net unrealized gain of $675,157 during the nine months ended September 30, 2017 compared with a net unrealized loss of $3,016,398 during the nine months ended September 30, 2016. The unrealized gains/losses can be attributed to fair value calculations undertaken periodically on the warrant and conversion feature liabilities recorded by us at the time the convertible debt and promissory notes were issued. Accordingly the warrant and conversion feature liabilities are increased or decreased based on the fair value calculations made at each quarterly balance sheet date. These non-cash gains and losses have materially impacted our results of operations during the nine months ended September 30, 2017 and September 30, 2016 and can be reasonably anticipated to materially affect our net loss or net income in future periods. The fair value calculations are heavily reliant on the value of our common stock and on the calculated volatility of the price of our common stock on the OTCQX Marketplace. Accordingly, significant changes in our stock price will create large unrealized gains and losses on our financial statements. We are, however, unable to estimate the amount of such income/expense in future periods as the income/expense is partly based on the market price of our common stock at the end of a future measurement date. In addition, if we issue securities in the future which are classified as derivatives we will incur expense and income items in future periods. Investors are cautioned to consider the impact of this non-cash accounting treatment on our financial statements.

Table of Contents

The below table contains the cumulative arrearage for each series of preferred stock as of September 30, 2017.

Series of Preferred Stock	Cumulative Arrearage
Series A	$	-0-
Series B		609,887
Series C		1,472,093
Total preferred stock arrearages	$	2,081,980

The three months ended September 30, 2017 compared to the three months ended September 30, 2016

Results of Operations

A summarized version of our results of operations for the three months ended September 30, 2017 and September 30, 2016 is included in the table below.

Summarized Statement of Operations
For the three months ended
September 30,
				% of						% of			$			%
	2017			Revenues			2016			Revenues			Change			Change
Total revenues	$	6,715,913					$	6,806,411					$	(90,498	)		-1.3	%

Total cost of goods sold		1,315,445			19.6	%		1,211,205			17.8	%		104,240			8.6	%

Gross margin		5,400,468			80.4	%		5,595,206			82.2	%		(194,738	)		-3.5	%

Salaries, benefits and related taxes		3,393,915			50.5	%		2,897,917			42.6	%		495,998			17.1	%
Rent		292,669			4.4	%		299,085			4.4	%		(6,416	)		-2.1	%
Consulting services		64,488			1.0	%		63,284			0.9	%		1,204			1.9	%
Legal and professional fees		126,959			1.9	%		78,449			1.2	%		48,510			61.8	%
Other expenses		408,520			6.1	%		328,892			4.8	%		79,628			24.2	%
Selling, general and administrative		277,047			4.1	%		298,072			4.4	%		(21,025	)		-7.1	%
Total operating expenses		4,563,598			68.0	%		3,965,699			58.3	%		597,899			15.1	%

Operating income/(loss)		836,870			12.5	%		1,629,507			23.9	%		(792,637	)		-48.6	%

Interest expense		(380,073	)		-5.7	%		(365,831	)		-5.4	%		(14,242	)		3.9	%
Interest income		3			0.0	%		-0-			0.0	%		3			n/a
Change in derivatives		(812,535	)		-12.1	%		(557,562	)		-8.2	%		(254,973	)		-45.7	%
Transaction gain/(loss)		(3,104	)		0.0	%		(11,728	)		-0.2	%		8,624			73.5	%

Income/(loss) before income taxes and dividends		(358,839	)		-5.3			694,386			10.2	%		(1,053,225	)		151.7	%
Income tax (expense)		-0-			0.0	%		(1,010	)		0.0	%		1010			100.0	%

Net income/(loss) attributable to common stockholders	$	(358,839	)		-5.3	%	$	693,376			10.2	%	$	(1,052,215	)		151.8	%

Table of Contents

The table below provides a comparison of our recognized revenues for the three months ended September 30, 2017 and September 30, 2016.

	For the three months ended
Revenue activity	September 30, 2017				September 30, 2016				$ Change			% Change
Set-up fees	$	1,256,579	18.7	%	$	1,578,682	23.2	%	$	(322,103	)		-20.4	%
Change orders		352,782	5.3	%		262,231	3.9	%		90,551			34.5	%
Maintenance		1,371,203	20.4	%		1,218,149	17.9	%		153,054			12.6	%
Software licenses		2,444,604	36.4	%		2,002,239	29.4	%		442,365			22.1	%
Professional services		919,821	13.7	%		1,511,007	22.2	%		(591,186	)		-39.1	%
Hosting		370,924	5.5	%		234,103	3.4	%		136,821			58.4	%
Total	$	6,715,913	100.0	%	$	6,806,411	100.0	%	$	(90,498	)		-1.3	%

Overall revenue decreased by $90,498 or 1.3% for the three months ended September 30, 2017 compared with revenue for the three months ended September 30, 2016. This decrease is primarily the result of decreases in professional services and set-up fees revenues partially offset by increases in software licenses, maintenance and hosting revenues.

We recorded revenue of $5,077,629 including $1,525,942 from software licensing, $1,256,579 from set-up fees, and $1,001,970 from maintenance revenues associated with our TrialMaster suite during the three months ended September 30, 2017 compared with revenue of $4,887,764 that included $1,578,682 in set-up fees, $1,529,115 from software licensing and $774,272 in maintenance revenues during the three months ended September 30, 2016.

We recorded $469,712 in revenues associated with clients using the eClinical Suite during the three months ended September 30, 2017 compared with revenue of $388,649 for the three months ended September 30, 2016. eClinical Suite revenues are primarily comprised of license subscriptions and revenues associated with our hosting and maintenance services.

We recorded $224,054 in software licenses during the three months ended September 30, 2017 compared with revenue of $27,227 from software licenses for the three months ended September 30, 2016. We recorded $190,758 in revenues from maintenance and $54,900 from hosting activities associated with the eClinical Suite during the three months ended September 30, 2017 compared with revenue of $285,993 from maintenance and $63,775 from hosting activities for the three months ended September 30, 2016. Generally, these revenues are paid quarterly and are connected to hosting and client support for clients licensing the eClinical Suite.

We recorded revenue of $1,033,981, including $680,864 from software licensing and $173,887 from professional services, with clients utilizing our TrialOne EDC software for the three months ended September 30, 2017 compared with revenue of $1,322,480 including $414,333 from software licensing and $764,220 from professional services for the three months ended September 30, 2016. We are continuing to enhance our efforts at developing our sales and marketing campaign for the TrialOne application. TrialOne revenues are primarily comprised of license subscriptions, professional services and maintenance services.

We recorded revenue of $134,591 for the three months ended September 30, 2017 including $74,852 from professional services and $45,995 from maintenance associated with clients utilizing the Promasys EDC solution as compared to revenue of $139,468 for the three months ended September 30, 2016 including $31,564 from software licensing and $77,326 from maintenance.

Table of Contents

Our top five customers accounted for approximately 35% of our revenues during the three months ended September 30, 2017 and approximately 38% of our revenues during the three months ended September 30, 2016. One customer accounted for approximately 14% and another accounted for approximately 10% of our revenues during the three months ended September 30, 2017. One customer accounted for approximately 14% and another accounted for approximately 11% of our revenues the three months ended September 30, 2016. The loss of any of these contracts or these customers in the future could adversely affect our results of operations.

Our international customers, who are principally located in Europe and East Asia, accounted for approximately 21% of our total revenues for the three month period ended September 30, 2017 and approximately 16% of our total revenues for the three months ended September 30, 2016.

Cost of goods sold increased approximately 9% or $104,240 for the three months ended September 30, 2017 as compared to the three months ended September 30, 2016. Cost of goods sold were approximately 20% of revenues for the three months ended September 30, 2017 compared to approximately 18% for the three months ended September 30, 2016. Cost of goods sold relates primarily to (i) salaries and related benefits associated with the programmers, developers and systems analysts producing clinical trials on behalf of our clients and (ii) the costs associated with pass-through revenues (reimbursable revenues). Cost of goods sold increased during the three months ended September 30, 2017 primarily due to an increase in salaries and related benefits. The pass-through revenue and expense primarily relate to specific work being performed for a few clients. At this time we do not expect the volume of the pass-through revenue and expense to grow significantly and therefore we do not expect any significant degradation of our gross margin.

Overall, total operating expenses increased approximately 15% for the three months ended September 30, 2017 compared to the three months ended September 30, 2016. The increase in operating expenses is primarily the result of an increase in salaries, benefits and related taxes.

Salaries and related expenses were our biggest operating expense at approximately 74% of total operating expenses for the three months ended September 30, 2017 compared to approximately 73% of total operating expenses for the three months ended September 30, 2016. Salaries and related expenses increased by 17% for the three months ended September 30, 2017 compared to the three months ended September 30, 2016. The table below provides a summary of the significant components of salary and related expenses by primary cost category.

	For the three months ended
Expense Category	September 30, 2017		September 30, 2016		$ Change			% Change
OmniComm corporate operations	$	2,345,258	$	2,026,366	$	318,892			15.7	%
New Jersey operations office		255,625		230,619		25,006			10.8	%
OmniComm Europe, GmbH		165,778		190,621		(24,843	)		-13.0	%
OmniComm Ltd.		222,079		163,559		58,520			35.8	%
OmniComm Spain S.L.		119,543		93,892		25,651			27.3	%
OmniComm Systems B.V.		79,628		134,646		(55,018	)		-40.9	%
Employee stock compensation		206,004		58,214		147,790			253.9	%
Total salaries and related expenses	$	3,393,915	$	2,897,917	$	495,998			17.1	%

During the three months ended September 30, 2017 and the three months ended September 30, 2016 we incurred $206,004 and $58,214, respectively, in salary expense in connection with ASC 718, Compensation – Stock Compensation, which establishes standards for transactions in which an entity exchanges its equity instruments services from employees. This standard requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.

Table of Contents

Rent and related expenses decreased by approximately 2% during the three months ended September 30, 2017 compared to the three months ended September 30, 2016. The table below details the significant portions of our rent expense. Our primary data site is located at a co-location facility in Cincinnati, Ohio and we will continue utilizing this facility for the foreseeable future since it is designed to ensure 100% production system up-time and to provide system redundancy. We also utilize co-location and disaster recovery space in the Fort Lauderdale, Florida area. This facility provides us with disaster recovery and business continuity services for our operations. In 2015 we added a third co-location facility in Frankfurt, Germany. We currently lease office space in Bonn, Germany for our European subsidiary, OmniComm Europe, GmbH under a lease that expires in July 2018. We currently lease office space for a regional operating office in New Jersey under a lease that expires in March 2021. Our OmniComm Ltd. subsidiary leases office space in Southampton, UK under a lease that expires in September 2020. Our OmniComm Systems B.V. subsidiary leases office space in Leiden, the Netherlands under a lease that expires in October 2018. Our Fort Lauderdale corporate office lease expires in February 2023. The table below provides the significant components of our rent related expenses by location or subsidiary. Included in rent during the three months ended September 30, 2017 was a decrease in expense of $1,363 in non-cash, straight line rent recorded to give effect to contractual, inflation-based rent increases in our leases compared to an increase in expense of $3,516 for the three months ended September 30, 2016.

	For the three months ended
Expense Category	September 30, 2017			September 30, 2016		$ Change			% Change
Corporate office	$	104,652		$	101,883	$	2,769			2.7	%
Co-location and disaster recovery facilities		136,300			142,898		(6,598	)		-4.6	%
New Jersey operations office		13,148			13,148		-0-			0.0	%
OmniComm Europe, GmbH		20,751			19,792		959			4.8	%
OmniComm Ltd.		14,821			14,373		448			3.1	%
OmniComm Spain S.L.		2,463			1,677		786			46.9	%
OmniComm Systems B.V.		1,897			1,798		99			5.5	%
Straight-line rent expense		(1,363	)		3,516		(4,879	)		-138.8	%
Total	$	292,669		$	299,085	$	(6,416	)		-2.1	%

Consulting services expense increased slightly to $64,488 for the three months ended September 30, 2017 compared with $63,284 for the three months ended September 30, 2016. Consulting services are comprised of fees paid to consultants for help with product development and for services related to our sales and marketing efforts. Product development consulting expenses increased year over year as we utilized the services of additional consultants during the three month period ended September 30, 2017. The table provided below provides the significant components of the expenses incurred related to consulting services.

	For the three months ended
Expense Category	September 30, 2017		September 30, 2016		$ Change			% Change
Sales and marketing	$	18,000	$	31,500	$	(13,500	)		-42.9	%
Product development		46,488		31,784		14,704			46.3	%
Total	$	64,488	$	63,284	$	1,204			1.9	%

Legal and professional fees increased approximately 62% for the three months ended September 30, 2017 compared with the three months ended September 30, 2016. Professional fees include fees paid to our auditors and accountants for services rendered on a quarterly and annual basis in connection with our filings with the Securities and Exchange Commission (“SEC”) and fees paid to our attorneys in connection with representation in matters involving litigation and acquisitions or for services rendered to us related to securities and SEC related matters. The table below compares the significant components of our legal and professional fees for the three months ended September 30, 2017 and September 30, 2016, respectively.

Table of Contents

	For the three months ended
Expense Category	September 30, 2017			September 30, 2016		$ Change			% Change
Financial advisory	$	25,500		$	-0-	$	25,500			n/a
Audit and related		7,018			5,808		1,210			20.8	%
Accounting services		82,970			40,391		42,579			105.4	%
Legal-employment related		(1,176	)		11,767		(12,943	)		-110.0	%
Legal-financial related		11,235			14,510		(3,275	)		-22.6	%
General legal		1,412			5,973		(4,561	)		-76.4	%
Total	$	126,959		$	78,449	$	48,510			61.8	%

Selling, general and administrative expenses (“SG&A”) decreased by $21,025 or approximately 7% for the three months ended September 30, 2017 compared to the three months ended September 30, 2016. SG&A expenses relate primarily to costs incurred in running our offices in Fort Lauderdale, Florida, Somerset, New Jersey, Southampton, England, Barcelona, Spain, Bonn, Germany and Leiden, the Netherlands on a day-to-day basis and other costs not directly related to other captioned items in our income statement. SG&A includes the cost of office equipment and supplies, the costs of attending conferences and seminars and other expenses incurred in the normal course of business. In 2016 we spent approximately $712,000 on marketing, sales and advertising. We expect that the 2017 marketing, sales and advertising expenses will be approximately $800,000 as we increase our attendance at tradeshows and our marketing efforts worldwide.

During the three months ended September 30, 2017 we recognized bad debt expense of $87,366 compared to $24,555 for bad debt expense for the three months ended September 30, 2016. This change was primarily the result of an increase in aged receivable balances that prompted us to increase our reserve. During the remainder of 2017 we will continue to carefully and actively manage our potential exposure to bad debt by closely monitoring our accounts receivable and proactively taking the action necessary to limit our exposure. We have been very successful in managing and collecting our outstanding accounts receivable. We believe that our current allowance for uncollectible accounts accurately reflects any accounts which may prove uncollectible during the remainder of 2017.

Interest expense was $380,073 for the three months ended September 30, 2017 compared to $365,831 for the three months ended September 30, 2016, an increase of $14,242. Interest incurred to related parties was $252,585 during the three months ended September 30, 2017 and $237,377 for the three months ended September 30, 2016. Included in interest expense is the accretion of discounts recorded related to financial instrument derivatives that were deemed a part of the financings we undertook in 2008 and 2009 and relating to warrants issued during 2011 and 2016. Interest expense increased year over year primarily due to the accretion of the discount from the derivatives associated with debt that was issued. The table below provides detail on the significant components of interest expense for the three months ended September 30, 2017 and September 30, 2016.

	For the three months ended
Debt Description	September 30, 2017		September 30, 2016		$ Change			% Change
Accretion of discount from derivatives	$	118,806	$	61,429	$	57,377			93.4	%
August 2008 convertible notes		48,394		48,394		-0-			0.0	%
December 2008 convertible notes		130,195		137,773		(7,578	)		-5.5	%
September 2009 secured convertible debentures		11,820		21,929		(10,109	)		-46.1	%
General interest		29,006		53,356		(24,350	)		-45.6	%
Related party notes payable		41,852		42,950		(1,098	)		-2.6	%
Total	$	380,073	$	365,831	$	14,242			3.9	%

We record unrealized gains/losses related to changes in our derivative liabilities associated with the issuance of convertible debt that occurred during 2008 and 2009 and warrants associated with promissory notes issued in 2011 and 2016. We recorded a net unrealized loss of $812,535 during the three months ended September 30, 2017 compared with a net unrealized loss of $557,562 during the three months ended September 30, 2016. The unrealized gains/losses can be attributed to fair value calculations undertaken periodically on the warrant and conversion feature liabilities recorded by us at the time the convertible debt and promissory notes were issued. Accordingly the warrant and conversion feature liabilities are increased or decreased based on the fair value calculations made at each quarterly balance sheet date. These non-cash gains and losses have materially impacted our results of operations during the three months ended September 30, 2017 and September 30, 2016 and can be reasonably anticipated to materially affect our net loss or net income in future periods. The fair value calculations are heavily reliant on the value of our common stock and on the calculated volatility of the price of our common stock on the OTCQX Marketplace. Accordingly, significant changes in our stock price will create large unrealized gains and losses on our financial statements. We are, however, unable to estimate the amount of such income/expense in future periods as the income/expense is partly based on the market price of our common stock at the end of a future measurement date. In addition, if we issue securities in the future which are classified as derivatives we will incur expense and income items in future periods. Investors are cautioned to consider the impact of this non-cash accounting treatment on our financial statements.

Table of Contents

Liquidity and Capital Resources

Liquidity is the ability of a company to generate adequate amounts of cash to meet its operating, investing and financing needs for cash. We have historically experienced negative cash flows and have relied on the proceeds from the sale of debt and equity securities to fund our operations. At September 30, 2017, we had working capital deficit of $7,506,044.

The table provided below summarizes key measures of our liquidity and capital resources:

Liquidity and Capital Resources
Summarized Balance Sheet Disclosure
	September 30, 2017			December 31, 2016			$ Change			% Change
Cash	$	1,317,591		$	1,439,332		$	(121,741	)		-8.5	%
Accounts receivable, net of allowance for doubtful accounts		5,415,730			5,455,210			(39,480	)		-0.7	%
Prepaid expenses		243,434			195,915			47,519			24.3	%
Prepaid stock compensation, current portion		-0-			148,422			(148,422	)		-100.0	%
Other current assets		32,140			35,055			(2,915	)		-8.3	%
Current assets		7,008,895			7,273,934			(265,039	)		-3.6	%

Accounts payable and accrued expenses		1,612,757			2,123,073			(510,316	)		-24.0	%
Patent litigation settlement liability, current portion		521,723			862,500			(340,777	)		-39.5	%
Deferred revenue, current portion		7,131,466			7,250,061			(118,595	)		-1.6	%
Convertible notes payable, current portion, net of discount		50,000			50,000			-0-			0.0	%
Conversion feature liability, related parties		1,555,297			1,740,278			(184,981	)		-10.6	%
Conversion feature liability		86,913			585,452			(498,539	)		-85.2	%
Warrant liability, related parties		2,317,324			2,519,614			(202,290	)		-8.0	%
Warrant liability		1,239,459			1,479,748			(240,289	)		-16.2	%
Current liabilities		14,514,939			16,610,726			(2,095,787	)		-12.6	%

Working capital (deficit)	$	(7,506,044	)	$	(9,336,792	)	$	1,830,748			19.6	%

Statement of Cash Flows Disclosure
	For the nine months ended
	September 30, 2017			September 30, 2016			$ Change			% Change
Net cash provided by/(used in) operating activities	$	1,279,921		$	631,591		$	648,330			102.7	%
Net cash provided by/(used in) investing activities		(212,173	)		(220,672	)		8,499			3.9	%
Net cash provided by/(used in) financing activities		(1,184,750	)		25,000			(1,209,750	)		4839.0	%

Net increase/(decrease) in cash and cash equivalents		(121,741	)		405,525			(527,266	)		-130.0	%

Changes in operating accounts		(1,407,312	)		(784,058	)		(623,254	)		-79.5	%

Effect of non-cash transactions on cash and cash equivalents	$	292,687		$	3,594,479		$	(3,301,792	)		-91.9	%

Cash and Cash Equivalents

Cash and cash equivalents decreased by $121,741 to $1,317,591 at September 30, 2017 from $1,439,332 at December 31, 2016. The decrease is primarily comprised of a net income of $2,394,546, changes in working capital accounts of ($1,407,312) and a increase from non-cash transactions of $292,687. During the nine months ended September 30, 2017 we had investing activities comprised of net purchases of property and equipment of $212,173. We had financing activities that included the repayment of $1,020,000 of notes payable and the repayment of $200,000 on our revolving line of credit during the nine month period ended September 30, 2017.

Table of Contents

Capital Expenditures

We are not currently bound by any long or short-term agreements for the purchase or lease of capital expenditures. Any amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately service any increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future.

Presently, we have approximately $200,000 planned for capital expenditures to further develop our infrastructure to allow for growth in our operations during the remainder of 2017. We expect to fund these capital expenditure needs through a combination of vendor-provided financing, the use of operating or capital equipment leases and cash provided from operations.

Contractual Obligations

The following table sets forth our contractual obligations as of September 30, 2017:

Contractual obligation			Payments due by period
	Total		Less than 1 year			1-2 Years			2-3 Years			3+ Years
Promissory notes (1)	$	1,102,500	$	-0-		$	400,000	(2)	$	702,500	(3)	$	-0-
Convertible notes (1)		6,170,000		50,000	(4)		150,000	(5)		5,770,000	(6)		200,000	(7)
Lines of credit (8)		2,500,000		-0-			-0-			2,500,000			-0-
Operating lease obligations (9)		2,248,288		712,455			529,679			350,944			655,210	(10)
Patent licensing fees (11)		525,000		525,000			-0-			-0-			-0-
Total	$	12,545,788	$	1,287,455		$	1,079,679		$	9,323,444		$	855,210

1. Amounts do not include interest to be paid.

2. Includes $400,000 in 12% notes payable that mature in April 2019.

3. Includes $420,000 in 10% notes payable that mature in April 2020 and $282,500 in 12% notes payable that mature in April 2020.

4. Includes $50,000 in 10% convertible notes currently in default and due that are convertible into shares of common stock at the option of the holder at a conversion rate of $1.25 per share.

5. Includes $150,000 in 10% convertible notes that mature in April 2019.

6. Includes $1,770,000 in 10% convertible notes that mature in April 2020 and $4,000,000 in 12% convertible notes that mature in April 2020.

7. Includes $200,000 in 12% convertible notes that mature in April 2021.

8. Includes $2,500,000 due on the revolving Line of Credit with The Northern Trust Company.

9. Includes office lease obligations for our Corporate Office in Florida, our regional operating office in New Jersey, our co-location and disaster recovery locations in Ohio, Florida and Germany, our office in England, our office in the Netherlands and our European headquarters in Germany.

10. Includes office lease obligations through 2023.

11. Relates to guaranteed minimum payments owed in connection with our settlement of a patent infringement lawsuit brought against the Company by DataSci, LLC.

Off Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Debt Obligations

As of September 30, 2017 we were in default on principal and interest payments owed totaling $141,949 on our 10% Convertible Notes that were issued in 1999.

On February 29, 2016 the Company issued a promissory note in the principal amount of $450,000 and warrants to purchase 1,800,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2019 to Mr. Wit in exchange for accrued interest in the amount of $450,000. The note carries an interest rate of 12% per annum and has a maturity date of April 1, 2019. On August 31, 2017 the Company repaid $50,000 to Mr. Wit.

On June 30, 2016 the Company and Mr. Wit extended the maturity date of $1,770,000 of convertible debentures to Mr. Wit originally issued in August 2008. The debentures carry an interest rate of 10% and have a maturity date of April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020.

On June 30, 2016 the Company and Mr. Wit extended the maturity date of $4,055,000 of convertible debentures to Mr. Wit originally issued in December 2008. The debentures carry an interest rate of 12% and have a maturity date of April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020. On August 31, 2017 the Company repaid $55,000 to Mr. Wit.

Table of Contents

On June 30, 2016 the Company and the holders extended the maturity date of $625,000 of convertible debentures originally issued in September 2009. The debentures carry an interest rate of 12% and have a maturity date of April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020. On August 24, 2017 the Company repaid $400,000 and on August 31, 2017 the Company repaid $225,000.

On June 30, 2016 the Company and the holder extended the maturity date of $100,000 of convertible debentures originally issued in December 2008. The debentures carry an interest rate of 12% and have a maturity date of April 1, 2020. The expiration date of the warrants associated with the debentures was also extended to April 1, 2020. On August 31, 2017 the Company repaid $100,00 of convertible debentures.

On June 30, 2016 the Company and our former director, Mr. van Kesteren ("Mr. van Kesteren") extended the maturity date of $150,000 of convertible debentures originally issued in August 2008. The debentures carry an interest rate of 10% and have a maturity date of April 1, 2018. The expiration date of the warrants associated with the debentures was also extended to April 1, 2018. On June 30, 2017 the Company and Mr. van Kesteren extended the maturity date of $150,000 of convertible debentures originally issued in August 2008. The debentures carry an interest rate of 10% and have a maturity date of April 1, 2019. The expiration date of the warrants associated with the debentures was also extended to April 1, 2019.

On June 30, 2016 the Company issued promissory notes in the principal amount of $420,000 and warrants to purchase 1,680,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2020 to two investors, in exchange for existing promissory notes in the same amount. The notes carry an interest rate of 10% per annum and have a maturity date of April 1, 2020.

On June 30, 2016 the Company issued promissory notes in the principal amount of $372,500 and warrants to purchase 1,490,000 shares of common stock of the Company at an exercise price of $0.25 per share with an expiration date of April 1, 2020 to two investors, in exchange for existing promissory notes in the same amount. The notes carry an interest rate of 12% per annum and have a maturity date of April 1, 2020.

On April 7, 2017 the Company renewed the Line of Credit. The Line of Credit currently matures on April 7, 2020 and carries a variable interest rate based on the prime rate. At September 30, 2017, $2,500,000 was outstanding on the Line of Credit at an interest rate of 3.25%.

On June 30, 2017 the Company and our former director, Mr. van Kesteren ("Mr. van Kesteren") extended the maturity date of $150,000 of convertible debentures originally issued in August 2008. The debentures carry an interest rate of 10% and have a maturity date of April 1, 2019. The expiration date of the warrants associated with the debentures was also extended to April 1, 2019.

On June 30, 2017 the Company and the holder extended the maturity date of $200,000 of convertible debentures originally issued in December 2008. The debentures carry an interest rate of 12% and have a maturity date of April 1, 2021. The expiration date of the warrants associated with the debentures was also extended to April 1, 2021.

On June 30, 2017 the Company repaid $100,00 of 12% convertible debentures originally issued in September 2009.

On August 31, 2017 the Company repaid $90,000 of 12% promissory notes originally issued to Mr. van Kesteren in 2014.

During the next twelve months we expect debt in the aggregate amount of $50,000 to mature as follows:

●

$50,000 of 10% convertible notes currently in default and due that are convertible into shares of common stock at the option of the debenture holder at a conversion rate of $1.25 per share.

Sources of Liquidity and Capital Resources

Because of the losses we have experienced from operations we have needed to continue utilizing the proceeds from the issuance of debt and the sale of equity securities to fund our working capital needs. We have used a combination of equity financing, short-term bridge loans and long-term loans to fund our working capital needs. Other than our revenues, current capital and capital we may raise from future debt or equity offerings, the $5,000,000 revolving line of credit with The Northern Trust Company ($2,500,000 of which is outstanding as of September 30, 2017) or short-term bridge loans, we do not have any additional sources of working capital.

We may continue to require substantial funds to continue our research and product development activities and to market, sell and commercialize our technology. We may need to raise substantial additional capital to fund our future operations. Our capital requirements will depend on many factors, including the problems, delays, expenses and complications frequently encountered by companies developing and commercializing new technologies; the progress of our research and product development activities; the rate of technological advances; determinations as to the commercial potential of our technology under development; the status of competitive technology; the establishment of collaborative relationships; the success of our sales and marketing programs; the cost of filing, prosecuting, defending and enforcing intellectual property rights; and other changes in economic, regulatory or competitive conditions in our planned business. Estimates about the adequacy of funding for our activities are based upon certain assumptions, including assumptions that our research and product development programs relating to our technology can be conducted at projected costs and that progress towards broader commercialization of our technology will be timely and successful. There can be no assurance that changes in our research and product development plans or other events will not result in accelerated or unexpected expenditures.

Table of Contents

While we have not sought capital from venture capital or private equity sources we believe that those sources of capital remain available although possibly under terms and conditions that might be disadvantageous to existing investors.

To satisfy our capital requirements, including ongoing future operations, we may seek to raise additional financing through debt and equity financings. There can be no assurance that any such funding will be available to us on favorable terms or at all. If adequate funds are not available when needed, we may be required to delay, scale back or eliminate some or all of our research and product development programs, and our business operations. If we are successful in obtaining additional financings, the terms of such financings may have the effect of diluting or adversely affecting the holdings or the rights of our stockholders or impose restrictive covenants that may adversely impact our business. Further, there can be no assurance that even if such additional capital is obtained or planned cost reductions are implemented, that we will achieve positive cash flow or profitability or be able to continue as a business.

While several of our officers and directors have historically, either personally or through funds with which they are affiliated, provided substantial capital either in the form of debt or equity financing there can be no assurance that they will continue to provide any such funding to us on favorable terms or at all.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires management to make judgments, assumptions and estimates that affect the amounts reported. Note 2 of Notes to the Condensed Consolidated Financial Statements describes the significant accounting policies used in the preparation of the condensed consolidated financial statements. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.

A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: 1) we are required to make assumptions about matters that are highly uncertain at the time of the estimate; and 2) different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.

Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes. These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. In addition, our Management is periodically faced with uncertainties, the outcomes of which are not within our control and will not be known for prolonged periods of time. Based on a critical assessment of its accounting policies and the underlying judgments and uncertainties affecting the application of those policies, our Management believes that our condensed consolidated financial statements are fairly stated in accordance with accounting principles generally accepted in the United States (GAAP), and present a meaningful presentation of our financial condition and results of operations.

Our Management believes that the following are our critical accounting policies:

ASSET IMPAIRMENT

Asset Acquisitions and Intangible Assets

We account for asset acquisitions in accordance with ASC 350, Intangibles-Goodwill and Other. The acquisition method of accounting requires that assets acquired and liabilities assumed be recorded at their fair values on the date of an asset acquisition.

Table of Contents

Long Lived Assets

FAIR VALUE MEASUREMENT

DEFERRED REVENUE

Deferred revenue represents cash advances and accounts receivable in excess of revenue earned on on-going contracts. Payment terms vary with each contract but may include an initial payment at the time the contract is executed, with future payments dependent upon the completion of certain contract phases or targeted milestones. In the event of contract cancellation, the Company is generally entitled to payment for all work performed through the point of cancellation.

REVENUE RECOGNITION POLICY

OmniComm’s revenue model is transaction-based and can be implemented either as an ASP (application service provider) or licensed for implementation by a customer such as a pharmaceutical company. Revenues are derived from the set-up of clinical trial engagements; licensing arrangements, fees earned for hosting our clients’ data and projects, on-going maintenance fees incurred throughout the duration of an engagement; and fees for report writing and project change orders. The clinical trials that are conducted using our EDC applications can last from a few months to several years. Most of the fees associated with our product including post-setup customer support in the form of maintenance charges are recognized ratably over the term of clinical trial projects. Cost of sales is primarily comprised of programmer salaries and taxes and is expensed as incurred.

The Company recognizes revenues, for both financial statement and tax purposes in accordance with SEC Staff Accounting Bulletin No. 104 “Revenue Recognition in Financial Statements (SAB 104)” (Codified within Accounting Standards Codification (ASC) Revenue Recognition ASC 605) and AICPA Statement of Position 97-2 (SOP 97-2) “Software Revenue Recognition” as amended by SOP 98-9 (Codified within ASC 605.985, Software Industry Revenue Recognition). SAB 104 requires that revenues be recognized ratably over the life of a contract. The Company will periodically record deferred revenues relating to advance payments in contracts. Under its licensing arrangements, the Company recognizes revenue pursuant to SOP 97-2. Under these arrangements, the Company recognizes revenue when all of the following conditions are satisfied: (1) there is persuasive evidence of an arrangement; (2) the service has been provided to the customer and/or delivery has occurred; (3) the collection of fees is probable; and (4) the fee is fixed or determinable. SOP 97-2, as amended, requires revenue earned on software arrangements involving multiple elements to be allocated to each element based on the relative fair values of the elements. We have analyzed each element in our multiple element arrangements and determined that we have sufficient vendor-specific objective evidence (“VSOE”) to allocate revenues to license updates and product support. License revenues are recognized on delivery if the other conditions of SOP 97-2 are satisfied. License updates and product support revenue is recognized ratably over the term of the arrangement. In arrangements where term licenses are bundled with license updates and product support and such revenue is recognized ratably over the term of the arrangement, we allocate the revenue to license revenue and to license updates and product support revenue based on the VSOE of fair value for license updates and product support revenue on perpetual licenses of similar products.

STOCK BASED COMPENSATION.

The Company accounts for its employee equity incentive plans under ASC 718, Compensation–Stock Compensation (“ASC 718”) which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions.

ASC 718 requires companies to estimate the fair value of share-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Consolidated Statements of Income. The Company currently uses the Black-Scholes option pricing model to determine grant date fair value.

Table of Contents

EFFECT OF RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

During the first nine months of 2017, we adopted the following new accounting pronouncements:

Accounting standards-setting organizations frequently issue new or revised accounting rules. We regularly review all new pronouncements that have been issued since the filing of our Form 10-K for the year ended December 31, 2016 to determine their impact, if any, on our financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable to smaller reporting companies.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, being September 30, 2017, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures, as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) are effective such that the information relating to OmniComm, including our consolidating subsidiaries, required to be disclosed by the Company in reports that it files or submits under the Exchange Act (1) is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (2) is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act, during the third quarter ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 1A. RISK FACTORS

In addition to the information set forth in this Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A of our most recent Annual Report on Form 10-K, which could materially affect our business, financial condition, or future results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

Table of Contents

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The following documents are filed as a part of this report or are incorporated by reference to previous filings, if so indicated:

EXHIBIT NO.	DESCRIPTION
10.47* †	Form of Promissory Note and Schedule of Substantially Identical Promisory Notes
10.48* †	Form of Extension of Maturity Date of Convertible Debenture [and related warrants] and Schedule of Substantially Identical Extensions of Maturity Date of Convertible Debenture [and related warrants]
10.58*	Lease Agreement Extension (Southampton, United Kingdom) dated September 10, 2017
31.1*	Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*	Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**	Certification of Principal Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Document
101.DEF*	XBRL Taxonomy Extension Definition Document
101.LAB*	XBRL Taxonomy Extension Label Document
101.PRE*	XBRL Taxonomy Extension Presentation Document

*	Filed herewith

**	Furnished herewith

†	Pursuant to Instruction 2 of Item 601(a) of Regulation SK, the Company has filed only the form of the contract, and other contracts substantially identical in all material respects, except as to the parties thereto and certain other details, are described in a Schedule to the exhibit.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 13, 2017

OMNICOMM SYSTEMS, INC.

By: /s/ Cornelis F. Wit

Cornelis F. Wit, Executive Chairman

(Principal Executive Officer)

By: /s/ Thomas E. Vickers

Thomas E. Vickers, Chief Financial Officer

(Principal Financial Officer)

Attached files

Stock widget

Investing forum

OMNICOMM SYSTEMS INC Reports